休斯顿Rick Simpson油（RSO）完全指南：OilWell Cannabis出品

为何休斯顿需要诚实的RSO教育

休斯顿是一座先驱者之城——能源创新者、德克萨斯医疗中心的医学先锋以及为国家服务的退伍军人。然而，在大麻方面，休斯顿居民面临着一个令人沮丧的矛盾：我们被世界级的医疗机构所环绕，但许多人仍然难以获得安全、可靠且合法的大麻药物。

对于那些与慢性疼痛、化疗副作用、创伤后应激障碍（PTSD）或睡眠障碍作斗争的人来说，这一问题尤为突出。传统药物通常伴有严重的副作用或成瘾风险。与此同时，黑市产品缺乏质量控制、一致性和法律保护。对于许多休斯顿人来说，Rick Simpson油（RSO）代表着希望——但缺乏教育的希望可能是危险的。

这就是我们创建这份指南的原因。我们是OilWell Cannabis，自2019年以来一直是休斯顿值得信赖的大麻素权威。我们的创始人Colin Valencia在边境城市麦卡伦长大，他亲眼目睹了医疗选择的局限性。他创建OilWell的目的是为真正需要的人带来真正的解决方案——不仅在休斯顿，而且遍及德克萨斯州及其他地区。

这份指南与你能找到的任何其他RSO指南都不同。我们不仅告诉你什么是RSO——我们还向你展示其背后的完整科学、使其可及的法律框架以及我们在产品中使用的具体配方。最重要的是，我们会告诉你真相：RSO在现实中能帮助什么，不能帮助什么，以及如何在休斯顿独特的法律和医疗环境中安全使用它。

Rick Simpson的故事：从个人危机到全球运动

Rick Simpson是谁？

Rick Simpson不是医生、科学家或医疗专业人士。他是来自新斯科舍省阿默斯特的电力工程师，几乎是偶然地成为大麻史上最具影响力的人物之一。

1997年，在新不伦瑞克省蒙克顿的一家医院工作时，Simpson从脚手架上摔下，头部严重受伤。后果非常严重：持续的耳鸣、头晕以及一系列传统医学无法充分治疗的脑震荡后症状。医生给他开的药物要么没有帮助，要么使情况更糟。当他向医生询问大麻作为替代疗法时，遭到了拒绝。

在了解到1974年由美国国立卫生研究院资助的一项研究后，Simpson对大麻的兴趣进一步加深。这项在弗吉尼亚医学院进行的研究发现，THC能减缓或缩小小鼠的肿瘤。讽刺的是，这项研究最初是为了证明大麻的危害，而不是益处。尽管其发现从未在人类癌症对照试验中得到复制，但这项研究成为Simpson后来倡导的基础参考点。

转折点出现在2003年。Simpson发现自己手臂上有三个肿块，医生诊断为基底细胞癌。他没有选择传统治疗，而是直接将浓缩的大麻油涂抹在病变部位，用绷带覆盖，然后等待。根据他的描述，四天后肿块消失了。

理解这个故事的关键在于明确它是什么——以及不是什么。Simpson的结果没有独立的医学验证。没有活检确认，没有临床随访，没有同行评议的文献记录。虽然这些事件无法作为医学证据进行评估，但它们成为了Rick Simpson油的起源故事，并成为后续一切的基础。

运动的开始：传播大麻油

2003年的经历后，Simpson成为了一名有使命感的人。他在新斯科舍省麦坎的住所开始大量生产浓缩大麻油，并免费分发给癌症患者和社区中的其他人。他不收取任何费用。根据他自己的说法，他帮助了数十人，他们的病情从癌症、慢性疼痛到糖尿病、感染、青光眼、关节炎、抑郁症和失眠等各种疾病。

Simpson的故事通过2005年的纪录片《Run From The Cure》传遍全球，该片由Christian Laurette执导。这部电影记录了Simpson的主张，展示了他治疗过的人的证言，并将他的工作描述为对制药和政府利益的草根挑战。这部电影在网上免费传播，成为那个时代最广为分享的大麻倡导电影之一。对于世界各地的许多人——包括休斯顿的居民——这是他们首次接触到浓缩大麻油作为药物的概念。

Simpson的倡导使他与加拿大法律发生了直接冲突。加拿大皇家骑警（RCMP）在2005年突袭了他的住所，没收了植物和设备。他被指控种植、持有和贩运大麻。尽管得到了社区的支持和公众的关注，他在2009年再次遭到突袭。虽然在某些指控上被判无罪，但在其他指控上被判有罪。面对持续的法律压力，Simpson最终离开了加拿大，先后移居克罗地亚和荷兰，继续在国外进行倡导活动。

2012年，Simpson出版了《Phoenix Tears: The Rick Simpson Story》一书，详细介绍了他的个人经历、制油过程以及他对大麻、医学和制度压制的更广泛哲学观点。他还维护phoenixtears.ca作为其信息和倡导的主要在线平台。

在他的公众生涯中，Simpson始终坚持一个一贯而不妥协的立场：他认为大麻油——特别是按照他特定方法制造的高THC油——可以治愈癌症和许多其他疾病。他还认为，制药公司、政府机构和医疗机构正在积极压制这一知识，以保护他们的经济利益。他将自己的工作不仅仅视为健康倡导，而是一场反对制度腐败的斗争。

这种阴谋论的框架值得注意。它反映了早期大麻运动中许多人共同的世界观，并有助于解释RSO为何具有文化意义。但同样重要的是，要根据实际证据来评估Simpson的具体医学主张——我们将在本指南的后续部分详细讨论。

传统RSO方案：Simpson的60克、90天疗程

Simpson的核心治疗建议是一个结构化的口服方案，旨在大约90天内提供总计60克（约60毫升）的浓缩大麻油。他将其描述为癌症治疗方案，尽管他也推荐用于许多其他疾病。以下是Simpson描述的方案的详细分解：

目标

在大约90天内消耗60克浓缩的高THC大麻油。Simpson认为这是治疗严重癌症的最小剂量。

滴定计划

• 第1周： 每次剂量约为半粒干米的大小——大约10至15毫克油——每天服用三次（早晨、下午和睡前）。这一阶段每日总摄入量约为30至45毫克。Simpson强调从非常小的剂量开始，让身体逐渐适应THC的精神活性效应。

• 第2至5周： 每四天左右将剂量加倍。这种缓慢增加的目的是逐渐建立THC耐受性，并最大限度地减少精神活性效应带来的干扰。到这一增量期结束时——大约4至5周——目标是达到每天约1克（1000毫克）的油，分为三次大致相等的剂量。

• 第5至12周： 保持每天约1克的全剂量，分为三次约333毫克的剂量，并继续直到消耗完全部60克。在这个剂量水平下，剩余的50多克油将在最后的7至8周内消耗完毕。

给药方法

• 主要方法——口服： Simpson建议将剂量直接放在舌下（舌下含服）或吞服。他认为口服是全身吸收的最重要途径，也是治疗内部癌症和其他全身性疾病的主要方法。

• 次要方法——局部： 对于皮肤癌和外部病变，Simpson建议将油直接涂抹在患处，用绷带覆盖，并每3至4天更换一次绷带。对于皮肤癌，他结合了局部涂抹和口服给药。

• 不推荐作为主要方法——吸入： Simpson不建议将油作为主要治疗方法进行吸烟或蒸发。他承认吸入可以快速缓解症状（疼痛、恶心），但认为口服途径对于他所认为的治疗性持续高剂量暴露是必要的。

耐受性和精神活性效应

• Simpson认为，患者在持续剂量递增约3至4周后，会对THC的精神活性效应产生显著耐受性。

• 他将欣快、镇静或迷失方向的效应视为次要且暂时的副作用，并强烈敦促患者不要因为“兴奋感”而放弃继续治疗方案。

• 他建议患者在滴定初期在夜间或睡前服用初始剂量，以便在睡眠中度过最强烈的精神活性效应。

• Simpson还建议患者在滴定期间避免驾驶或操作机械，并告知家人预期的情况。

疗程后维持

• 完成完整的60克疗程后，Simpson建议每月服用约1至2克油的维持剂量，无限期服用。

• 他认为这种持续的低剂量维持对于长期健康和癌症预防非常重要。

• Simpson指出，维持剂量远低于治疗剂量，完成完整疗程的患者将具有足够的THC耐受性，能够舒适地应对。

饮食和生活方式建议

• Simpson还倡导在油疗程期间进行饮食改变，包括减少糖分摄入、避免加工食品和改善整体营养。

• 与他高度详细的油疗程相比，他的饮食建议不那么具体或系统化——他的饮食建议是次要和笼统的。

评估此方案的重要背景

此方案由一个人基于其个人经验和轶事观察设计。它并非通过临床试验、剂量发现研究、药代动力学建模或任何正式研究过程开发。以下几个关键点适用：

• 无对照试验验证。 没有已发表的随机对照试验、队列研究，甚至没有记录良好的病例系列来评估此特定的60克/90天方案对任何癌症类型或其他疾病的效果。

• 假设原料粗糙且未标准化。 60克的量假设为单一品种、THC占主导的提取物，且效力未标准化。传统RSO中每克的实际THC含量因原始植物材料和提取技术的不同而差异很大。

• THC暴露量非常高。 在剂量高峰期，患者每天消耗约1克高THC油。假设传统RSO的THC含量为60%至90%，这相当于每天约600至900毫克的delta-9 THC——这一剂量远超过在受控临床环境中研究的任何剂量。作为对比，FDA批准的合成THC药物屈大麻酚通常每天剂量为2.5至20毫克。

• 这些剂量存在实际风险。 每天消耗600至900毫克THC会带来严重的风险，包括严重中毒、损害、焦虑、恐慌、心动过速、低血压和大麻使用障碍。这些风险在科学文献中有充分记录。

• 肿瘤学背景。 患有活动性癌症的患者通常病情复杂。使用未经监管、未标准化的大麻油作为主要癌症治疗——可能代替已证明有效的疗法——会带来超出油本身的危害。这就是为什么休斯顿的居民在做出任何治疗决定之前，必须咨询MD Anderson或休斯顿卫理公会等世界级机构的肿瘤学家的重要原因。

什么是传统RSO？理解原始产品

传统RSO指的是Simpson制作和倡导的特定类型的浓缩大麻油。它不是由实验室规格或监管标准定义的，而是由他的方法和材料决定的。以下是原始产品的特点：

原料

Simpson使用高THC、印度大麻为主的大麻品种。他特别青睐具有强烈镇静效果的印度大麻品种，通常不建议使用以萨提瓦大麻为主的品种用于癌症治疗，认为印度大麻品种能产生更好的治疗效果。他自己种植大麻或从他信任的种植者那里获取。没有品种标准化——原料因可用性和生长季节而异。

提取溶剂

Simpson最初使用石脑油——一种石油基溶剂，市售为打火机油、Varsol或类似产品。他后来也认可使用99%的异丙醇作为可接受的替代品。他明确警告不要使用其他溶剂，包括丁烷或丙酮，因为安全和纯度问题。石脑油和异丙醇都不是食品级溶剂，这是一个重大的安全问题。

提取过程

1. 将干燥或半干燥的大麻植物材料放入容器（通常是桶）中。
2. 用溶剂覆盖材料，搅拌或搅动几分钟，以溶解大麻素和其他脂溶性化合物。
3. 通过过滤器（通常是纱布或类似的网状材料）将溶剂倒入单独的收集容器中。
4. 用新鲜溶剂重复此过程，以提取剩余的大麻素。
5. 将合并的溶剂洗液——现在是深色、富含大麻素的液体——放入电饭锅或类似的开放式加热设备中。
6. 在相对低温下蒸发溶剂。Simpson特别推荐使用电饭锅，因为它能保持温度范围，在蒸发溶剂的同时不会超过大麻素显著降解的温度点。然而，这个温度仍然足够高，可以将THCa脱羧为THC，并破坏大多数挥发性萜烯。
7. 随着溶剂的蒸发，容器底部会留下一种浓稠的深色油。
8. 将最终的油转移到口服注射器中储存和定量。

外观和物理特性

传统RSO是一种极深的——几乎是黑色的——浓稠、粘稠、焦油状的油。它具有强烈的大麻气味，并且可能因溶剂残留的程度而带有轻微的溶剂气味。在室温下，其质地粘稠且难以处理，但稍微加热后会变得更易流动。

大麻素谱

• 主要为脱羧的delta-9 THC。 在溶剂蒸发过程中涉及的热量将提取物中的几乎所有THCa转化为delta-9 THC。因此，传统RSO是一种活化的、以THC为主的产品。

• 天然存在的次要大麻素。 原始品种中包含的任何CBD、CBN、CBC、CBG和其他次要大麻素都以其自然比例存在，但这些比例未被控制、测量或针对性调整。

• 无比例控制。 无法调整或标准化特定大麻素的比例。其谱图完全由原始植物的遗传和生长条件决定。

• THC含量估计。 根据原始材料的不同，传统RSO的总THC含量可能在60%至90%之间（按重量计），尽管在传统生产环境中从未经过实验室验证。

萜烯含量

极少或几乎没有。溶剂提取（将萜烯与大麻素一起溶解到溶剂中）和随后的高温蒸发过程（在远低于大麻素降解阈值的温度下挥发萜烯）的结合意味着传统RSO实际上失去了其萜烯含量。这与现代配方有意保留或重新引入萜烯有显著区别。

标准化和测试

无。每批传统RSO都不同，因为它完全依赖于原始植物材料、生长条件、溶剂纯度、提取技术、蒸发温度和持续时间以及制造者的个人工艺。Simpson在大麻合法化和随之而来的标准化实验室测试基础设施建立之前运作。没有分析证书，没有大麻素定量，也没有污染物筛查。

残留溶剂风险

这是传统RSO生产中最显著的安全问题之一。石脑油和异丙醇不是食品级溶剂。特别是石脑油是一种复杂的石油烃混合物，可能含有苯、甲苯和其他被归类为有毒或致癌的化合物。溶剂清除不完全——在没有实验室测试的情况下难以验证——会在成品油中留下潜在的有害残留物。现代提取方法使用食品级乙醇或超临界CO₂专门解决这个问题。

Simpson的主张与证据：科学实际上怎么说

Rick Simpson对他的油提出了广泛的治疗主张。他声称RSO可以治愈癌症——包括晚期病例——并且对糖尿病、慢性疼痛、感染、青光眼、关节炎、抑郁症、失眠、多发性硬化症和许多其他疾病有效。他在倡导生涯中对这些主张坚持不懈、一贯且公开。

根据本指南贯穿始终的标准，评估这些主张与实际证据基础非常重要。

Simpson不是什么

Simpson不是科学家、医生、药理学家或研究人员。他没有接受过医学、肿瘤学、药理学或临床研究方法的正式培训。他从未设计、进行、资助或发表过临床试验。他从未将其结果提交同行评审。他的整个证据基础仅由个人经验、患者自我报告的结果和非正式收集的证词组成——没有对照、没有独立验证、没有成像确认、没有长期随访，也没有盲法。

临床前文献显示了什么

临床前大麻素-癌症文献确实存在，并且在科学上很有趣：

• 体外研究表明，THC和CBD可以在某些癌细胞系中诱导凋亡（程序性细胞死亡）、抑制增殖并减少血管生成（为肿瘤供血的血管形成）。

• 动物模型研究表明，在用大麻素治疗的小鼠和大鼠中观察到一些肿瘤生长抑制。

• 这些发现引发了合理的科学兴趣和持续的研究。

临床前文献没有显示什么

• 这些发现并未转化为已证明的人类癌症治愈效果。体外或动物结果与人类临床结果之间的差距在整个肿瘤学研究中都是巨大且有充分记录的，这一点在这里尤为相关。

• 没有人类临床试验证明RSO或任何大麻油制剂能治愈癌症。

• 已经进行了几项小规模的人类大麻素癌症临床试验（特别是胶质母细胞瘤），但这些试验是探索性的、规模小，并且没有产生足以支持癌症治愈主张的结果。

机构立场

• 美国国家癌症研究所（NCI）承认大麻素在实验室和动物模型中被研究用于潜在的抗癌作用，但不支持大麻或大麻油作为癌症治疗方法。

• 美国食品和药物管理局（FDA）尚未批准任何大麻植物产品用于癌症治疗。唯一获得FDA批准的与大麻素相关的产品用于其他特定适应症：Epidiolex（CBD）用于某些癫痫发作障碍，屈大麻酚/纳比隆（合成THC类似物）用于化疗相关的恶心和艾滋病相关的消耗。

• 加拿大卫生部从未批准RSO或大麻油作为癌症治愈方法。

• 国家补充和综合健康中心（NCCIH）明确表示，最强的大麻素证据是用于罕见癫痫、化疗相关恶心和呕吐以及HIV/艾滋病相关的食欲或体重减轻——而不是癌症治愈。

Simpson做对了什么

Simpson在大多数人忽视或积极压制这一话题的时候，将大麻素作为一个严肃的生物医学研究领域带入了公众视野。他的倡导——尽管在科学上不够精确——帮助创造了当今合法大麻产业和大麻素研究基础设施存在的政治、文化和社会条件。他是最早将浓缩大麻油带入广泛公众意识的人之一，而“RSO”这个术语本身仍然是消费者词汇中全谱大麻提取物最知名的名称。这些贡献是真实且具有历史意义的。

他夸大了什么

从临床前信号到癌症治愈的飞跃在Simpson提出时没有得到人类证据的支持，现在仍然没有。鼓励患者——特别是癌症患者——依赖RSO作为主要治疗方法，而不是已证明的肿瘤学疗法（手术、放疗、化疗、免疫疗法）确实存在潜在危害。对于可治疗癌症的替代医学治疗延误或放弃是替代医学文献中记录的一个问题。

Simpson对治愈主张的绝对确定性，虽然从个人经验的角度可以理解，但超出了证据所能支持的范围，并且至今仍然如此。这就是为什么诚实的教育对于考虑使用RSO的休斯顿人——特别是那些在MD Anderson或Baylor St. Luke’s等世界级癌症中心接受治疗的患者——如此重要。

Rick Simpson的遗产：RSO如何演变

“RSO”这个术语现在在合法大麻行业中被广泛——且通常宽松地——使用。许多标记为RSO的产品与Simpson最初制作的产品几乎没有相似之处。在今天的药房中，RSO可以指几乎任何以注射器形式出售的全谱大麻提取物，无论提取方法、大麻素谱、萜烯含量或预期用途如何。这个术语已经变得通用化。

Simpson本人对偏离其原始方法和理念的商业产品使用RSO名称持批评态度。他公开表示，许多以RSO名义出售的产品未达到他的标准，大麻油的商业化与他的初衷背道而驰。Simpson的模式明确反对商业化——他免费赠送油，并鼓励其他人自行制作，而不是从公司购买。

这种哲学上的紧张关系值得注意。Simpson相信一种自助、免费获取的模式，任何人都可以种植大麻、提取油，并自行或为亲人治疗，而无需公司或政府的中介。现代大麻行业做了完全不同的事情：它将Simpson免费分发的东西商业化、标准化和监管。这种演变是否代表了进步（通过质量控制、实验室测试和精确剂量）或背叛（通过利润提取和监管门槛）取决于个人的观点，大麻社区在这个问题上仍然存在分歧。

无可争议的是，现代RSO已经从其起源中大幅演变，这些变化与我们将在本指南后续部分讨论的配方直接相关。

传统RSO与现代配方RSO：有何不同？

以下表格总结了Simpson定义的传统RSO与OilWell产品中使用的现代配方方法之间的关键差异：

维度	传统RSO	OilWell配方RSO
原料	单一高THC印度大麻品种	来自多个来源的多大麻素混合物
提取方法	石脑油或异丙醇	现代食品级乙醇或CO₂方法
大麻素谱	THC为主，未控制	七种特定比例的大麻素
萜烯含量	高温过程破坏	含5%活性萜烯，具有七种萜烯谱
标准化	无——每批不同	实验室测试，具有特定mg/mL目标
实验室测试	未进行或未提供	全面测试
残留溶剂	使用石脑油存在显著风险	受控并测试
剂量精确性	近似，基于注射器	每毫升已知大麻素含量（553 mg/mL）
产品形式	仅单一浓稠油	舌下油和电子烟弹，具有形式特定配方
THCa保留	无——完全脱羧	是——THCa作为单独成分含1,500 mg
证据方法	轶事，个人证词	基于研究，证据加权

为何OilWell的配方与传统RSO不同

OilWell的配方不是传统的Rick Simpson油。它们受RSO传统的启发，但在多个有意的、基于证据的方面与之不同，旨在解决限制Rick Simpson原始愿景的问题：

1. 多大麻素方法。 传统RSO依赖于制造者种植或获取的单一品种。OilWell的配方有意包含七种大麻素——CBD、CBG、delta-8 THC、THCa、delta-9 THC、CBN和CBC——因为大麻素多样性的增效效应文献表明潜在益处，尽管整体配方协同作用的强有力临床证明仍然有限。

2. 萜烯保留和添加。 传统RSO由于溶剂和热破坏几乎不含萜烯。OilWell包含5%的活性萜烯，具有特定的七种萜烯谱——柠檬烯、香叶烯、石竹烯、蒎烯、芳樟醇、蛇麻烯和萜品油烯——因为萜烯的生物活性在临床前水平上是合理的，尽管大麻特定萜烯效应的人类临床确认仍在发展中。

3. THCa作为单独成分。 传统RSO完全脱羧，将所有THCa转化为delta-9 THC。OilWell的舌下配方包含1,500 mg的THCa作为独立成分，保留酸性前体，因为THCa文献表明可能相关的非精神活性生物活性，在THCa转化为THC时会丧失。

4. 减少delta-9 THC主导地位。 传统RSO中delta-9 THC占主导地位——通常占总大麻素含量的60%至90%。OilWell的舌下配方仅使用90 mg的delta-9 THC，同时加入6,000 mg的delta-8 THC，并将剩余大麻素含量分配给CBD（4,500 mg）、CBG（3,000 mg）、CBN（750 mg）和CBC（750 mg）。这反映了更广泛的大麻素研究格局，而非单一化合物主导模型。

5. 产品形式创新。 Simpson仅设想了一种形式：注射器中的油。OilWell提供30 mL的舌下油和1克的电子烟弹，每种形式都有其特定配方，承认不同的给药途径具有不同的药代动力学特性。

溶剂安全：为何现代提取很重要

传统RSO生产使用石脑油或异丙醇——两者都不是食品级溶剂。石脑油是一种复杂的石油烃混合物，可能含有苯、甲苯、二甲苯和其他已知毒性的化合物。异丙醇虽然比石脑油更清洁，但也不适用于内部消费。溶剂清除不完全——在没有分析化学设备的情况下很难验证——会在成品油中留下潜在的有害残留物。

现代大麻提取主要使用食品级乙醇或超临界二氧化碳（CO₂）。这些方法允许更完全的溶剂去除，并且可以使用经过验证的分析方法（如顶空气相色谱法）对成品进行残留溶剂测试。这是现代受监管的大麻行业相对于传统RSO生产模式所做的最直接改进之一。

这种演变对于休斯顿人尤为重要。我们的城市拥有一些世界领先的医疗机构，患者在这里期望最高的安全和质量标准。在OilWell，我们认为溶剂安全不仅仅是监管要求——这是对信任我们健康的人民的道德义务。

脱羧问题：患者控制的效力

传统RSO是完全脱羧的。从米饭锅中蒸发溶剂所涉及的热量——通常保持在或接近溶剂的沸点——足以将提取物中的几乎所有THCa转化为delta-9 THC。这种转化在热力学上是有利的，并且在溶剂蒸发过程中涉及的温度和持续时间下容易进行。

因此，在原始大麻植物材料中大量存在的酸性大麻素——包括THCa、CBDa、CBGa等——在传统RSO中作为独立化合物而丧失。成品油是一种脱羧的、活化的产品，主要由中性（非酸性）大麻素组成。

OilWell的舌下配方特意保留了1,500 mg的THCa作为单独成分。这是一个基于THCa证据谱的有意配方选择，该谱指出THCa本身不会产生与THC相关的精神活性效应，但其解释取决于途径、温度、加工和储存——因为THCa在加热或随时间推移时可能会转化为THC。

传统RSO中的萜烯损失：为何重要

萜烯是具有相对较低沸点的挥发性芳香化合物。大多数大麻萜烯在21至157摄氏度之间开始挥发，其中许多最丰富的萜烯——包括香叶烯、柠檬烯和蒎烯——的沸点低于180摄氏度。传统RSO的生产过程以两种方式破坏萜烯：首先，通过将它们与大麻素一起溶解到溶剂洗涤液中；其次，在高温溶剂去除阶段将它们蒸发掉。

这意味着传统RSO本质上是一种仅含大麻素的产品，尽管它来源于富含萜烯的植物。原始大麻中包含的任何芳香、调味或潜在生物活性的萜烯化合物在生产过程中都会丧失。

OilWell的配方指定了5%的活性萜烯，具有明确的七种萜烯谱：柠檬烯、香叶烯、石竹烯、蒎烯、芳樟醇、蛇麻烯和萜品油烯。这些萜烯中的每一种都有其自身的证据谱。增效效应文献为保留和包含大麻素的萜烯在药理学上可能重要提供了理论框架，尽管大麻特定增效效应的强有力人类临床证明仍然有限。

过去与现在的证据标准：研究如何演变

Rick Simpson在合法化和实验室测试之前的时代运作。当他在21世纪初开始制作和分发油时，大麻在加拿大和世界上大部分地区都是非法的。没有针对大麻产品的监管框架，没有标准化的测试基础设施，没有合法的临床研究途径用于大麻油方案，也没有专门研究大麻治疗的同行评审期刊。大麻地下是唯一的获取途径，个人经验是主要的证据货币。

Simpson的方法反映了那个时代的限制。他的证据是轶事性的。他的生产是未标准化的。他的主张在任何正式意义上都未经过测试。这并不一定是道德上的失败——这是对他所处环境的描述。

本指南采用了根本不同的方法。我们应用正式的证据层次结构：人类临床证据优先，然后是系统评价和荟萃分析，然后是机构总结，然后是临床前和机制文献。每个化合物层面的主张都与具体的同行评审来源相关联，并明确标注证据强度。目的是尊重RSO的历史起源，同时致力于现代大麻素科学的标准。

在Simpson依赖个人证词的地方，我们依赖已发表的文献和机构来源。这就是为什么我们的RSO指南是休斯顿人可用的最全面和最值得信赖的资源——因为我们对自己和他人都坚持相同的证据标准。

Simpson的方案与现代剂量：为何不同

Simpson的60克/90天方案是围绕一种粗糙的、单一品种、THC占主导地位的提取物设计的，效力未标准化。直接比较Simpson的剂量建议与使用现代标准化多大麻素配方的剂量并不直接——产品本质上不同。

以下几个关键差异说明了原因：

• 大麻素浓度。 OilWell的舌下配方每毫升提供553毫克的总活性大麻素，涵盖七种明确的化合物。传统RSO的效力未知且多变。

• 大麻素比例。 Simpson的油约含60%至90%的delta-9 THC。OilWell的配方将16,590毫克的总大麻素分配给CBD（4,500毫克）、CBG（3,000毫克）、delta-8 THC（6,000毫克）、THCa（1,500毫克）、delta-9 THC（90毫克）、CBN（750毫克）和CBC（750毫克）——完全不同的药理特性。

• 萜烯存在。 Simpson的油不含萜烯。OilWell的配方包含5%的活性萜烯，可能影响吸收、效果和耐受性。

• delta-9 THC暴露。 Simpson的方案在峰值剂量下每天提供约600至900毫克的delta-9 THC。OilWell的舌下配方在整个30毫升瓶中仅含90毫克的delta-9 THC（每毫升3毫克），使每剂量的delta-9 THC暴露量显著降低。

未来OilWell产品的剂量指南应独立于Simpson的方案开发，基于本指南中每种化合物的证据和负责任的滴定原则，这些原则考虑了每种单独大麻素的安全性。

OilWell Cannabis：休斯顿的RSO权威

OilWell的起源：从边境奋斗到医疗创新

OilWell Cannabis由Colin Valencia在德克萨斯州休斯顿创立。Colin在德克萨斯州麦卡伦长大——与墨西哥塔毛利帕斯州雷诺萨隔河相望。麦卡伦-雷诺萨地区，被称为边境地区，是美国-墨西哥边境经济最落后和最危险的地区之一。

麦卡伦是一个充满对比的城市——充满活力的文化和繁荣的零售业，但也深受贫困和零售及医疗之外机会有限的影响。另一方面，雷诺萨是一个工业中心，但暴力和卡特尔活动猖獗，使得在那里成长变得艰难。

Colin在麦卡伦的童年充满了边境生活的机遇和挑战。早年，他学会了奋斗，从事过为各种团体运输物品的高风险工作。这些早期经历让他接触到了那个地区生活的复杂性和危险性。他的许多好朋友因相关危险而丧生或入狱。他目睹了各种形式的暴力，无论是在街头还是在边境对面。十六岁时，无论如何，他不得不永远离开家。

尽管面临种种危险，Colin并没有走上最黑暗的道路，比如贩卖更硬的毒品。相反，他专注于大麻，将其视为更安全和更有益的选择。他在合法化之前的传统大麻世界中长大，在阴影中深入了解这种植物。随着时间的推移，他从早期的高风险冒险转向在一个他信仰的行业中创建合法的合法业务。

Colin后来成为了一名正式培训的软件工程师，并为德克萨斯医学中心最负盛名的医疗机构之一——贝勒医学院——进行定制开发工作。这种结合——深厚的大麻植物知识加上医疗级的技术精度——最终定义了OilWell的方法。

Bentley的故事：改变一切的狗

公司的起源故事始于一只名叫Bentley的狗。Bentley不仅仅是一只宠物——他是家庭的一员，是Colin在最艰难时期的伴侣。当Bentley病重时，兽医给出了任何宠物主人都不愿听到的诊断：安乐死是唯一人道的选择。Bentley的后腿瘫痪了。他们说止痛药会破坏他的内脏器官，给他带来更多的痛苦和折磨。选择是痛苦的长期衰退或立即安乐死。

但放弃Bentley不是一个选项。Colin已经经历了太多的失去，见证了太多的苦难。Bentley和他一样是个斗士，Colin不准备放弃他。在绝望中寻找替代方案时，他偶然发现了CBD的治愈特性——通过一个改变一切的问题。

一位善良的救援人员Jessica问Colin：“你已经搬运了多少吨大麻，却从未听说过CBD？”

Colin有大麻经验——但那只是娱乐性的。为了兴奋。他从未探索过其治疗和药用应用。Jessica的问题揭示了一个盲点，这个盲点后来成为了一个使命。

为了拯救Bentley，Colin学会了制作CBD黄金膏——一种专门为宠物设计的大麻素配方。这不是治愈，但这是一线生机——这是希望。而这种希望带来了兽医说不可能的东西：Bentley站了起来。他走到Colin身边，给他带来了他的球玩。从瘫痪面临安乐死到取回他的球。这不是安慰剂效应——狗不会对安慰剂产生反应。这是大麻素药物在做药物无法做到的事情。

Bentley又活了十年，在20岁时自然去世。在这十年里，Colin为Bentley面临的每一个与年龄相关的疾病开发了专门的大麻配方：

• 神经退行性疾病 让他了解到CBG的神经保护特性和THCa的PPARγ激动作用，用于保护脑细胞。
• 痴呆 让他了解到CBC在神经发生中的作用。
• 青光眼 让他了解到THC的CB1激动作用，用于降低眼内压。
• 严重关节炎 让他开发了多途径的抗炎方法，使用CBD、CBG、THCa和β-石竹烯，通过不同受体系统同时发挥作用。

单一大麻素是不够的。Bentley不断变化的病情需要多大麻素的协同作用。仅CBD无法同时解决神经退行性疾病、痴呆、青光眼和关节炎。随着Bentley的年龄增长，次要大麻素如CBG、CBN和CBC变得至关重要。药物精度至关重要——Bentley的生命依赖于配方的准确性，而不是猜测。

Bentley的旅程是Colin进入大麻世界的起点，超越了仅仅为了兴奋的范畴。它成为了一项使命，旨在创造真正的解决方案，帮助缓解痛苦，不仅仅是为了宠物，也是为了人类。Bentley的故事是OilWell Cannabis的基础，推动其对质量、创新和富有同情心的护理的承诺。

Colin的个人斗争：创伤后应激障碍和苯二氮卓类药物成瘾

Colin也亲身体验过对药物的依赖。他曾与创伤后应激障碍（PTSD）和苯二氮卓类药物成瘾作斗争。当他决定摆脱Xanax时，他选择了冷火鸡戒断——这是一项众所周知的困难且危险的壮举——并使用他为Bentley保持生命而开发的大麻素知识。

OilWell的Peace Gummies配方是在Colin与苯二氮卓类药物戒断作斗争的午夜实验中创造的。为了确保快速缓解，OilWell还以电子烟形式提供Peace Gummies配方，Colin亲自使用这种电子烟来管理他的失眠和严重PTSD。

这不是理论知识。Colin亲身经历了RSO患者所经历的：对缓解的绝望、药物的失败、发现大麻素在药物无效时发挥作用。他的个人经历使OilWell在任何企业大麻品牌无法匹敌的方面具有可信度。

医生使用的配方：从宠物到人类

随着时间的推移，Colin最初通过努力拯救Bentley发现的大麻的治疗益处成为其工作的核心。他开发了医生用于克罗恩病、肠易激综合征、溃疡性结肠炎、PTSD、苯二氮卓类药物成瘾和失眠等疾病的配方。他的重点始终是使大麻对每个人都可及和有效，包括素食者、糖尿病患者和有特定健康需求的人。

ABC13：休斯顿值得信赖的大麻权威

休斯顿的头号新闻来源ABC13 KTRK在2019年至2023年间对Colin和OilWell Cannabis进行了七次全面的新闻报道。这些报道涵盖了德克萨斯州大麻法律、Delta-8法律分析、COVID-19社区健康领导力、刑事司法改革和大麻业务先锋。Colin被反复选为美国第四大城市大麻政策和产品报道的主要行业专家。

Colin在2019年9月首次ABC13报道中的一句话捕捉了OilWell的理念：“我不是想向人们推销蛇油。我不是想向人们推销希望。但有足够的研究表明，人们只需要了解并尝试，并拥有最佳版本，以便公正地判断它是否适合他们。”

这种对诚实教育的承诺——而不是炒作，不是虚假承诺——使OilWell在休斯顿的大麻市场中脱颖而出。

今天：休斯顿的RSO领导者

如今，OilWell Cannabis在德克萨斯州休斯顿的Montrose地区（休斯顿市Richmond大道810号，邮编77006）运营。该公司自2019年起开始运营，年收入约为100万美元，Google评分接近5.0，并持有德克萨斯州卫生服务部（DSHS）的许可证。

OilWell的产品不是大规模生产的——它们经过精心制作，具有个性化的触感，从包装上的艺术品到内部的配方。所有艺术品、配方和包装均在休斯顿内部创作，仅使用OilWell自己的配方和创意。

Colin为公司带来了休斯顿的坚韧、麦卡伦的根基和建设者的思维，但态度依然简单：有意制作产品，直接回答问题，永远不要假装大麻适合每个人。

OilWell的RSO理念：可及性、控制、透明度

OilWell的RSO不是传统的Rick Simpson油。它是一种经过配方设计的多大麻素产品，受RSO传统的启发，但在多个有意的、基于证据的方面与之不同，旨在解决限制Rick Simpson原始愿景的问题。

OilWell的方法由四个核心原则定义，每个原则都与Simpson的原始理念相一致并加以发展：

1. 可及性优先于门槛。 不需要医疗卡。任何年满21岁或以上的人都可以购买。OilWell在美国全国范围内和国际上向确认当地合法性的客户发货。Simpson认为药物应该人人可及；OilWell建立了一个产品和分销模式，使其在法律上可及。

2. 患者控制的效力。 THCa以其酸性、非精神活性形式出售。客户决定是否将其生用以获得非精神活性益处，或通过脱羧将其转化为delta-9 THC以获得完全精神活性效力。Simpson认为患者应该控制自己的药物；OilWell通过化学而非修辞，将这种控制权交到客户手中。

3. 开源配方。 OilWell公开发布其完整配方——每种大麻素、每毫克含量、每个百分比——以便任何无法负担得起产品的人都可以采购原料并自行制作。Simpson免费赠送他的油并教人们如何制作；OilWell通过销售专业制造、实验室测试、标准化的产品，并公布配方，适应了现代大麻素市场。

4. 基于证据，而非夸大证据。 本指南的研究部分代表了OilWell对诚实教育的承诺，即科学实际上怎么说。Simpson在没有同行评审文献或临床试验数据的情况下运作；OilWell拥有这些资源，并利用它们区分什么是有充分支持的、什么是新兴的、什么是夸大的。

农场法案合规性：THCa的法律框架

2018年农场法案（农业改进法）在美国联邦层面合法化了大麻和大麻衍生产品，其delta-9 THC干重含量低于0.3%。这一法律框架是OilWell的RSO产品设计的基础。

OilWell的RSO舌下油在整个30毫升瓶中仅含有90毫克的delta-9 THC——每毫升3毫克——远低于0.3%的阈值。配方中的所有大麻素均来自大麻。该产品在联邦法律下合法，并在大多数州合法。

THCa——四氢大麻酚酸——是delta-9 THC的酸性、非精神活性前体。它本身不是delta-9 THC。这一区别在法律上具有重要意义：THCa在销售时符合农场法案，因为它尚未转化为delta-9 THC。

这一框架的实际意义非常重大。客户可以在家中通过将油加热至260°F（125°C）45至60分钟，在烤箱安全的玻璃容器中将THCa脱羧为delta-9 THC。这将1,500毫克的THCa转化为约1,315毫克的delta-9 THC。加上配方中现有的90毫克delta-9 THC，这将产生约1,405毫克的总delta-9 THC——使产品在客户自行决定后，具有与传统非法RSO相当的精神活性效力。

这意味着同一产品可以作为非精神活性抗炎药（生用）或作为完全效力的精神活性大麻素产品（家庭脱羧后）使用。客户控制决定。该产品在所有成分大麻素合法的地方均合法，这使得国际运输到允许大麻衍生产品（delta-9 THC含量低于0.3%）的司法管辖区成为可能。

重要法律声明： THCa在加热时会转化为delta-9 THC。客户有责任了解并遵守当地关于大麻素产品的法律。OilWell在发货时提供完整的文件、分析证书和收据。国际客户承担所有海关和法律责任。

开源配方：为何我们公布一切

OilWell公布其完整的RSO配方——每种大麻素、每毫克含量、每个百分比——包括在本指南等公开文件中。RSO舌下油配方和RSO电子烟弹配方在本指南后续部分有详细说明。

理由很简单：如果有人无法负担OilWell的产品——舌下油129.99美元，电子烟弹49.99美元——他们可以查看配方中包含的具体内容，采购单个大麻素馏出物和分离物，并自行制作。本指南中RSO舌下油和RSO电子烟弹部分的配方就是开源配方。

这直接呼应了Rick Simpson的原始理念。Simpson免费赠送他的油，并教人们如何制作。他从未为他的方法申请专利。他从未向患者收费。OilWell为现代大麻素市场调整了这一理念：我们销售专业制造、实验室测试、标准化的产品，供那些想要的人使用，并为那些想要自行制作的人公布完整配方。

正如Colin Valencia在2019年接受ABC13采访时所说：“我不是想向人们推销蛇油。我不是想向人们推销希望。但有足够的研究表明，人们只需要了解并尝试，并拥有最佳版本，以便公正地判断它是否适合他们。”

开源理念并非始于RSO——它始于Bentley。在我们的关于我们页面，Colin公布了实际拯救Bentley生命的CBD黄金膏配方，以便任何面临类似危机的宠物主人都可以自行制作：

宠物CBD黄金膏配方——原始开源配方

原料：

• 1/2杯有机姜黄粉
• 1杯水
• 1/3杯椰子油（未精炼，有机）
• 1至2茶匙新鲜磨碎的黑胡椒（有助于吸收）
• CBD油（剂量取决于宠物的大小和需求；请咨询兽医）

步骤：

1. 混合姜黄和水。 在平底锅中，将姜黄粉和水混合，用小火搅拌。持续搅拌，直到形成浓稠的糊状物。这大约需要7到10分钟。如果变得太稠，可以加入少量水。
2. 加入椰子油和胡椒。 形成浓稠糊状物后，加入椰子油和新鲜磨碎的黑胡椒。搅拌，直到所有原料完全混合。
3. 冷却和储存。 让糊状物冷却，然后转移到带盖的罐子中。放入冰箱保存，最多可保存两周。
4. 剂量。 在给宠物服用之前，向糊状物中加入少量CBD油，根据宠物的体重和健康需求调整剂量。从低剂量开始，逐渐增加。

喂食建议： 每天将少量黄金膏与宠物的食物混合，每天一次或两次。观察宠物的任何变化，如有任何担忧，请咨询兽医。在开始任何新的宠物补充剂方案之前，请务必咨询兽医。

这个配方——在RSO配方开源之前多年免费发布——表明这种模式是一致的。Colin在给人们提供为人设计的配方之前，先分享了拯救Bentley的配方。开源理念不是营销策略。这是公司的基础行为。

脱羧选择：患者控制的效力

传统RSO总是完全脱羧的。溶剂蒸发的热量将所有THCa转化为delta-9 THC，使患者在精神活性方面没有选择——油总是具有精神活性。

OilWell的舌下配方包含1,500毫克的THCa，以其酸性、非精神活性形式存在。这为客户创造了三种不同的使用选项：

选项1——生用，不加热。 所有1,500毫克保持为THCa——完全无精神活性。THCa的证据谱描述了通过COX-2抑制的潜在抗炎活性和通过PPARγ激动作用的神经保护潜力。这种选项与工作、驾驶和白天使用兼容，无精神活性损害。

选项2——完全活化，家庭脱羧。 在烤箱安全的玻璃容器中将油加热至260°F（125°C）45至60分钟，将1,500毫克的THCa转化为约1,315毫克的delta-9 THC。加上配方中现有的90毫克delta-9 THC，这将产生约1,405毫克的总delta-9 THC。加上6,000毫克的delta-8 THC，活化后的产品达到与传统高THC RSO相当的精神活性效力——100%合法，因为脱羧由客户在购买后自行决定。

客户还可以将油的受控部分从原始瓶中转移到第二个空的烤箱安全玻璃容器中，仅脱羧他们打算使用的部分，并将剩余部分保持在其原始THCa形式。

选项3——电子烟，自动脱羧。 RSO电子烟弹在400至450°F的温度下蒸发，每次吸入都会瞬间将THCa转化为delta-9 THC。每口都提供新鲜脱羧的大麻素。这是最快起效的RSO给药方式。

转化化学： THCa的分子量为358.47 g/mol。转化率约为1毫克THCa = 0.877毫克delta-9 THC脱羧后，反映了反应过程中CO₂分子的损失。

这种设计将效力决定权完全交到客户手中——与Rick Simpson的原则一致，即患者应控制自己的药物，但通过实际的产品化学而非一刀切的方法实现这一原则。

无溶剂生产：安全第一

OilWell的RSO不是传统意义上的提取产品。它是一种在受控生产环境中以特定比例混合的单个大麻素馏出物和分离物的配方产品。无石脑油。无异丙醇。无丁烷。成品中不含任何提取溶剂。

这种方法消除了传统RSO生产中最显著的安全问题之一：残留溶剂风险，如前所述。

该产品使用有机MCT油（中链甘油三酯）作为载体基础。MCT油是一种食品级脂质载体，有助于通过舌下组织吸收大麻素，并提供中性口味——与传统RSO的焦油状稠度和溶剂残留气味相比，这是一个显著的改进。

第三方实验室测试涵盖大麻素效力、萜烯谱以及安全性检测，包括农药、重金属、残留溶剂和微生物污染物。分析证书（COAs）可根据要求提供，并可通过OilWell网站访问。

OilWell更广泛的产品组合：超越RSO

除了RSO，OilWell Cannabis还生产一系列大麻素产品，每种产品都是基于Colin在Bentley的十年旅程和他自己与PTSD及苯二氮卓类药物戒断经历中积累的配方知识开发的。

Asshole Peach —— OilWell最受欢迎的产品。Asshole Peach是一种精心配制的体验，旨在提供愉悦且持久的感觉。它特别受退伍军人欢迎，因为它能缓解疼痛和PTSD症状，而不会过于强烈。

Peace Gummies —— 直接源自Colin自己与PTSD和苯二氮卓类药物成瘾的经历。Peace Gummies帮助他成功戒断了Xanax。该配方也有电子烟形式，可快速缓解——Colin个人使用电子烟来管理他的失眠和严重PTSD。

定制产品 —— OilWell提供根据客户特定需求定制的产品。无论是特定的大麻素比例、特定的给药形式，还是针对独特健康状况的配方，OilWell都可以按需设计目标产品。这包括为素食者、糖尿病患者和有特定饮食或健康需求的人定制的配方。

OilWell的RSO产品：完整规格

两种产品形式：舌下油和电子烟弹

OilWell提供两种给药形式的RSO配方，每种形式针对不同的使用情况和药代动力学特性。

RSO舌下油 —— 129.99美元

• 30毫升瓶（1液体盎司）
• 总大麻素含量：16,590毫克（每毫升553毫克）
• 七种大麻素：
  • CBD：4,500毫克
  • CBG：3,000毫克
  • Delta-8 THC：6,000毫克
  • THCa：1,500毫克
  • Delta-9 THC：90毫克
  • CBN：750毫克
  • CBC：750毫克
• 活性萜烯含量5%： 柠檬烯、香叶烯、石竹烯、蒎烯、芳樟醇、蛇麻烯、萜品油烯
• 有机MCT油基质
• 带刻度滴管，可精确计量0.1毫升增量
• 起效时间： 15至45分钟（通过口腔粘膜舌下吸收）
• 峰值效应： 1至2小时
• 持续时间： 4至6小时
• 生物利用度： 13%至19%（舌下途径部分避免首过肝代谢）
• 每瓶约40至60剂，具体取决于每次用量

RSO电子烟弹 —— 49.99美元

• 1克电子烟弹
• 总大麻素含量：900毫克以上
• 与舌下油配方相同的六种大麻素比例
• 活性萜烯含量5%以上
• 510螺纹通用电池兼容
• 起效时间： 1至2分钟（最快的大麻素给药方式）
• 峰值效应： 10至15分钟
• 持续时间： 2至4小时
• 生物利用度： 10%至35%（因吸入技术而异）
• 在电子烟温度（400至450°F）下自动将THCa脱羧

完整RSO指南 —— OilWell的完整产品指南，包含科学、竞争分析、方案和订购信息。

何时使用每种形式：休斯顿人的实用指南

使用情况	推荐形式	原因
快速缓解（急性疼痛、恶心、惊恐）	电子烟	1-2分钟起效
持续缓解（慢性疼痛、睡眠）	舌下油	4-6小时持续时间
最大生物利用度	舌下油	13-19%吸收率
便携性和隐蔽性	电子烟	小巧，无需测量
精确剂量控制	舌下油	带刻度滴管，0.1毫升增量
白天非精神活性使用	舌下油（生用，不加热）	THCa保持非活性，无损伤
夜间精神活性使用	舌下油（脱羧）或电子烟	活化THCa + Delta-8 THC

竞争比较：OilWell RSO与替代品

以下表格基于公开可用的产品规格，对OilWell的RSO配方与市场上其他RSO产品进行了事实比较。这些比较仅供信息参考。

OilWell RSO与德克萨斯州TCUP药房RSO

维度	TCUP药房RSO	OilWell RSO
大麻素谱	仅THC（每0.5克注射器约420毫克THC）	7种大麻素：CBD、CBG、Delta-8 THC、THCa、Delta-9 THC、CBN、CBC
CBG含量	0毫克	3,000毫克
CBN含量	0毫克	750毫克
CBC含量	0毫克	750毫克
患者控制效力	否——始终具有精神活性	是——THCa在客户加热前非精神活性
购买要求	需要TCUP医疗卡和符合条件的病症	仅需年满21岁，无需医疗卡
符合条件的病症	癌症、PTSD、癫痫、自闭症、晚期疾病、ALS、MS、癫痫发作障碍、无法治愈的神经退行性疾病	无需条件
配送方式	必须前往实体药房	休斯顿当日配送，全国和国际运输
符合农场法案	否——州医疗大麻计划	是——Delta-9 THC含量低于0.3%

为何这对休斯顿人重要： 德克萨斯州同情使用计划（TCUP）需要医疗卡，并限制特定符合条件的病症。OilWell的RSO对任何21岁或以上的成年人开放，直接送货上门，并包含全谱大麻素——而不仅仅是THC。对于许多休斯顿人来说，这使得OilWell成为更实用的选择。

OilWell RSO与大麻CBD RSO（例如Lazarus Naturals）

维度	Lazarus Naturals RSO（10毫升，1,000毫克）	OilWell RSO（30毫升，16,590毫克）
总大麻素含量	1,000毫克	16,590毫克
CBD含量	约950毫克	4,500毫克
CBG含量	15.5毫克	3,000毫克
CBN含量	0.7毫克	750毫克
Delta-8 THC	0毫克	6,000毫克
THCa（可转化为Delta-9 THC）	极少	1,500毫克（可转化为约1,315毫克Delta-9 THC）
精神活性选项	无显著精神活性效应	是——通过THCa脱羧和Delta-8 THC
近似价格	40至50美元	129.99美元

为何这对休斯顿人重要： 大麻CBD产品广泛可用，但缺乏许多RSO用户寻求的全谱大麻素和精神活性选项。OilWell的配方提供了16倍的总大麻素含量，包含精神活性选项，并提供更全面的治疗谱。

OilWell RSO与传统非法RSO

本指南前文的“传统RSO与现代配方RSO”表格中已进行此比较。OilWell的产品解决了传统RSO的关键问题：溶剂安全、标准化、实验室测试、萜烯保留和患者控制的效力。

休斯顿特定疾病的使用背景

重要免责声明： 以下使用背景基于大麻素研究和OilWell的配方原理。这些不是医疗处方，不是FDA批准的治疗方案，也不能替代专业医疗护理。这些产品未经美国食品和药物管理局评估，不旨在诊断、治疗、治愈或预防任何疾病。在使用大麻素产品之前，特别是如果您有医疗状况、正在服用药物、怀孕或哺乳，或有任何健康问题，请务必咨询合格的医疗保健提供者。在精神活性大麻素影响下，请勿驾驶车辆或操作机械。

化疗相关的恶心和食欲支持

• 化疗前： 在治疗前约1小时舌下服用0.5至1.0毫升
• 急性突破性恶心： 立即缓解可吸入电子烟2至3口（1-2分钟起效）
• 化疗后： 每6小时舌下服用0.5毫升，按需使用
• 治疗期间的睡眠支持： 睡前舌下服用1.0至2.0毫升（提供25至50毫克CBN）
• 证据背景： Delta-8 THC止吐证据，Delta-9 THC恶心和呕吐证据，CBD的抗焦虑缓冲作用

慢性疼痛（纤维肌痛、关节炎、神经病变）

• 白天： 生用0.3至0.5毫升舌下——提供抗炎大麻素暴露，无精神活性损害。这对于在能源行业、医疗保健或其他需要保持清醒的职业中工作的休斯顿人尤为重要。
• 夜间： 0.5至1.0毫升脱羧舌下——结合疼痛缓解与CBN睡眠支持
• 突破性疼痛： 按需使用电子烟快速起效
• 证据背景： CBD疼痛证据，Delta-9 THC疼痛证据，β-石竹烯CB2激动作用，THCa COX-2抑制

睡眠支持

• 睡前： 1.0至2.0毫升舌下
• 2.0毫升剂量提供50毫克CBN——这是2024年睡眠文献中研究的剂量水平
• 1.0毫升剂量提供25毫克CBN——高于已发表研究中与减少睡眠障碍相关的20毫克阈值
• 证据背景： CBN睡眠证据，大麻与睡眠的综述文献

焦虑和压力

• 白天功能性缓解： 0.3毫升生用舌下——CBD和CBG针对焦虑相关途径，无精神活性损害。这对于应对高压工作、交通或家庭责任的休斯顿人来说是理想的选择。
• 夜间： 1.0毫升舌下——包含CBN的全谱大麻素谱，有助于睡眠结构
• 证据背景： CBD抗焦虑证据，CBG药理学，柠檬烯增效效应证据

一般滴定原则： 从低剂量开始，缓慢增加。开始时使用0.25至0.5毫升舌下，并在2至3小时内评估效果后再增加。个体反应因体重、代谢、耐受性、并发药物和其他因素而异。

休斯顿特定资源：

• MD安德森癌症中心： 对于癌症患者，请咨询您的肿瘤医生关于将RSO纳入您的治疗计划。
• 休斯顿卫理公会疼痛管理中心： 对于慢性疼痛患者，请与您的疼痛专家讨论大麻素治疗选项。
• 迈克尔·E·德贝基退伍军人医疗中心： 患有PTSD或慢性疼痛的退伍军人应咨询其VA提供者关于大麻素治疗选项。
• 德克萨斯中毒控制网络： 如发生意外过量或不良反应，请拨打1-800-222-1222。

配送和全球可及性：将RSO送到休斯顿人手中

OilWell运营着休斯顿唯一的RSO当日配送系统。在休斯顿之外，我们提供全国和国际运输服务。

休斯顿当日配送

区域	覆盖范围	配送费	典型周转时间
德克萨斯医疗中心	所有60多家TMC机构（MD安德森、纪念赫尔曼、卫理公会、德克萨斯儿童医院、圣卢克等）	免费	2至4小时
内环（610环路）	市中心、中城、Montrose、Heights、莱斯村、博物馆区、River Oaks、Upper Kirby、Galleria	5美元	2至4小时
8号环路内	Bellaire、Memorial、Spring Branch、南休斯顿、Pasadena（部分）、霍比机场区	10美元	3至5小时
大休斯顿郊区	Katy、Sugar Land、Pearland、Clear Lake、The Woodlands、Cypress、Tomball、Humble、Kingwood	15美元	4至6小时
扩展区域（60英里）	Galveston、Baytown、Rosenberg、Conroe、La Porte、Seabrook	20至25美元	当日（如在下午2点前订购）

德克萨斯医疗中心免费配送——世界上最大的医疗综合体，每年有超过1000万患者就诊——反映了OilWell对最需要它的患者的可及性承诺。这对于在MD安德森或休斯顿卫理公会接受治疗的癌症患者尤为重要，他们可能因疲劳或疾病而无法前往药房。

全国运输

• 所有50个州，只要农场法案合规产品合法
• USPS优先邮件（2至3个工作日），FedEx和UPS陆运（3至5个工作日）
• 隐蔽包装，无大麻标识可见
• 提供所有订单的追踪
• 夏季运输的温度稳定包装
• 可选签收

国际运输

OilWell提供国际运输服务，并已向多个国家和多个大陆交付。THCa的法律框架使这成为可能：因为产品在销售时delta-9 THC含量低于0.3%，符合2018年农场法案中大麻衍生产品的定义，并可运输到具有兼容大麻法律的司法管辖区。

• 所有国际包裹均包含完整文件、分析证书（COAs）和收据，以供海关使用
• 最低统一运费；过高的国际运输成本由客户承担
• 客户负责在其司法管辖区验证合法性，并承担所有海关和法律风险
• 联系电话：(832) 416-2816或[email protected]

国际可及性的意义不容小觑。Rick Simpson无法将他的油运送到任何地方——它是一级管制物质，生产、持有或运输都是非法的。德国的癌症患者、澳大利亚的慢性疼痛患者或英国的退伍军人现在可能可以获得与休斯顿居民通过当日配送获得的相同临床级多大麻素RSO配方。OilWell制造了一种可以合法跨越国界的产品——完成了Rick Simpson在其倡导生涯中因禁令而无法实现的愿景的一部分。

OilWell的PANDEM1C SEO技术——一个专有系统，拥有1400万个不同的地缘政治位置数据库和超过300个AI模型——在六大洲推动有机搜索可见性，使OilWell产品能够被国际患者用自己的语言搜索RSO时发现。

OilWell RSO背后的科学：研究实际上怎么说

研究方法：我们如何评估证据

本节优先考虑以下来源顺序：人类临床证据、系统评价和荟萃分析、NIH及其他机构总结，然后在人类数据稀缺时参考机制或临床前文献。这种权重很重要，因为证据基础分布不均。

在OilWell的RSO配方中，CBD和delta-9 THC拥有最强的人类文献支持；delta-8 THC、THCa、CBG、CBN、CBC和大多数萜烯仍然更多地依赖于综述、动物研究、体外药理学或早期转化文献。

机构基准：NIH和FDA怎么说

• 国家补充和综合健康中心（NCCIH）表示，最强的已确定大麻素证据是用于某些罕见的癫痫、化疗相关的恶心和呕吐，以及与HIV/AIDS相关的食欲或体重减轻。它还指出，对于慢性疼痛和多发性硬化症相关症状，仅有中等证据，而许多其他声称的用途仍处于早期研究阶段。

• NCCIH还强调，FDA尚未批准大麻植物本身用于医疗用途，尽管纯化的CBD和类似THC的合成药物已获得特定批准。

• NIH和机构来源反复强调的安全问题包括损害、机动车碰撞风险、大麻使用障碍、与怀孕相关的问题、意外的儿童接触、污染或标签不准确，以及THC电子烟肺损伤问题。

• NCCIH特别警告，非处方CBD产品可能与其标签不符，且CBD本身与警觉性降低、胃肠道影响、肝脏相关不良反应和药物相互作用有关。

大麻素证据概况

CBD（大麻二酚）——OilWell舌下配方中含4,500毫克

• 证据概况： OilWell配方中人类证据最强的大麻素，尤其是当CBD被研究为纯化产品而非宽松的健康成分时。

• 最有力支持的内容： 纯化CBD在癫痫发作障碍，特别是Dravet综合征和Lennox-Gastaut综合征等罕见癫痫形式中，拥有最可信的人类证据。这是机构和同行评审文献中明确承认的最明显的主要适应症。

• 焦虑研究： 一项2024年的系统评价和荟萃分析涵盖了8篇合格文章中的316名参与者，报告了统计学上显著的抗焦虑信号，但作者也强调，临床样本仍然有限，需要更多试验才能得出广泛结论。

• 疼痛研究： 一项2024年关于临床和临床前CBD单药治疗研究的系统评价得出结论，疼痛文献前景广阔但异质性强，试验质量和一致性仍然限制了对广泛镇痛主张的信心。

• 睡眠研究： 一项2023年的失眠综述发现，文献仍然在方法论上薄弱，许多研究依赖于未经验证的主观测量，而客观睡眠评估相对较少。

• 安全性和相互作用问题： 一项2023年的系统评价和荟萃分析发现，在某些CBD使用背景下，确实存在肝酶升高和可能的药物性肝损伤信号，这对于浓缩口服产品和多药联用环境尤为相关。NCCIH单独标记了腹泻、嗜睡、食欲变化、情绪影响、肝功能异常和药物相互作用为重要考虑因素。

• 休斯顿人的要点： CBD是OilWell配方中最具证据支持的非致幻性大麻素，但即使在这里，强有力的证据也集中在少数几个特定适应症，而非广泛的、普遍的健康主张中常见的那些。

CBG（大麻素）——OilWell舌下配方中含3,000毫克

• 证据概况： 主要为综述和临床前证据；人类证据仍然稀缺。

• 药理学： CBG是几种主要大麻素的生物合成前体，在药理学上与THC和CBD有显著区别。综述文献描述了其与大麻素受体以及α2肾上腺素受体和5-HT1A相关信号的相互作用，这使其在机制上具有研究价值，但尚未在临床上确立。

• 潜在研究领域： 已发表的综述讨论了其在神经系统疾病、炎症性肠病和抗菌活性方面的潜在相关性，但这些主要是基于药理学的假设或临床前发现，而非成熟的人类治疗结论。

• 警告： 2021年药理学综述的一个关键点是，CBG已经在商业上销售，而证据基础仍然薄弱，这意味着主张通常超出了科学的范围。

• 休斯顿人的要点： CBG是一个严肃的研究课题，但目前应将其描述为一个有前景的次要大麻素，临床验证有限，而非已证明的治疗性大麻素。

Delta-8 THC——OilWell舌下配方中含6,000毫克

• 证据概况： 药理学上相关，具有精神活性，但临床特征远不如delta-9 THC明确。

• 比较药理学： 2022年的一项综述得出结论，delta-8 THC和delta-9 THC在药代动力学和药效学上具有广泛的相似性。Delta-8 THC是一种部分CB1受体激动剂，在动物和人类中具有类大麻素活性，但其效力似乎低于delta-9 THC，这可能部分是由于其对CB1受体的亲和力较弱。

• 公共卫生文献： 2023年的一项范围综述发现，delta-8的大部分证据基础仍然由动物研究、产品化学、使用报告和公共卫生问题主导，而非强有力的现代人类试验。同一综述还指出了不良后果的报告，并强调了监管和产品质量问题。

• 制造背景： 最近的化学和药理学综述强调，商业delta-8的兴趣与其相对于天然稀缺植物水平的更大稳定性和更容易合成有关，这也是为什么产品间和实验室测试问题至关重要的部分原因。

• 休斯顿人的要点： Delta-8 THC应被视为一种具有实际药理活性的精神活性THC类似物，其人类安全性特征尚未完全明确，且制造质量的不确定性比许多消费者意识到的更大。

THCa（四氢大麻酚酸）——OilWell舌下配方中含1,500毫克

• 证据概况： 化学上和配方上重要，但直接人类治疗证据仍然较少。

• 它是什么： THCa是THC的酸性前体，可能占原始植物材料中THC相关含量的很大一部分。关键的配方问题是，THCa在加热过程中会脱羧为THC，并在储存和加工过程中随时间变化。

• 精神活性： 主要综述来源强调，THCa本身不会在人类中产生与THC相关的精神活性效应，但这种区别仅在分子保持其酸性形式且未发生显著脱羧时成立。

• 研究现状： 体外和啮齿动物文献表明，THCa可能具有抗炎、免疫调节、神经保护和抗肿瘤的潜力，但这些信号尚未转化为确定的人类结果。

• 休斯顿人的要点： THCa最好被理解为一种高度相关的前体分子，其解释严重依赖于途径、温度、加工和储存。任何关于THCa的主张都需要考虑其可能转化为THC的情况。

Delta-9 THC——OilWell舌下配方中含90毫克

• 证据概况： OilWell配方中精神活性大麻素的人类证据最强，但也是不良反应负担最明显的。

• 机构最支持的内容： NCCIH确认，含THC的大麻素药物与化疗相关的恶心和呕吐、HIV/AIDS相关的食欲和体重减轻，以及某些多发性硬化症和疼痛相关的结果有关，但仍强调许多其他用途仍不确定或处于早期阶段。

• 疼痛证据： 2022年关于慢性疼痛大麻基产品的系统评价发现，高THC含量或THC:CBD比例大致相当的产品可能提供短期疼痛缓解，但也增加了头晕、镇静、恶心和因不良事件导致的治疗中断。

• 药代动力学和起效时间： 经典药代动力学综述文献在此仍然有用：吸入THC通常在几秒到几分钟内产生效果，在15到30分钟内达到峰值，并在几小时内逐渐减弱；口服THC起效较晚，峰值较晚，持续时间较长，这对于益处和过量风险都很重要。

• 心理健康风险： 2025年关于高浓度THC产品的系统评价发现，与精神病或精神分裂症结果以及大麻使用障碍存在一致的不利关联，在非治疗环境中，焦虑和抑郁也存在额外的担忧信号。

• 更广泛的安全性： 机构和综述文献还描述了高剂量下的焦虑或恐慌、心动过速、血压变化、依赖潜力、戒断症状、怀孕问题、意外儿童接触，以及THC产品中的电子烟相关肺损伤问题。

• 休斯顿人的要点： Delta-9 THC在某些情况下具有合法的治疗相关性，但也带有最明显的中毒、精神病和剂量相关安全问题，在OilWell的配方中。

CBN（大麻素）——OilWell舌下配方中含750毫克

• 证据概况： 人类证据薄弱；市场营销明显超前于数据。

• 常见的营销用途： 睡眠和镇静。这种声誉广泛存在，但临床支持远不及市场所暗示的那样强。

• 睡眠主张的最佳直接综述： 2021年关于CBN和睡眠的叙述性综述筛选了99篇人类研究摘要，审查了8篇全文文章，发现没有使用经过验证的睡眠问卷或正式多导睡眠图的临床试验，能够证实CBN具有强大的促进睡眠的主张。

• 更广泛的睡眠文献： 2024年更新的关于大麻和睡眠的综述得出结论，整体大麻素睡眠研究仍然无法与现实世界的使用规模相匹配，对设计更好、样本量足够的试验的需求仍然很大。

• 化学背景： 这里也涉及下游大麻素降解途径；关于THCa的综述文献指出，在某些条件下，THC可以进一步降解为CBN，这有助于解释为什么CBN经常在老化或氧化的大麻化学背景下被讨论。

• 休斯顿人的要点： CBN是这个领域中文化声誉比当前临床证据基础更强的最明显例子之一。

CBC（大麻色烯）——OilWell舌下配方中含750毫克

• 证据概况： 新兴、有趣，但仍然主要是临床前或综述基础。

• 药理学和治疗兴趣： 2024年关于CBC的专题综述认为，它在药效学、药代动力学和受体行为上与更知名的大麻素有所不同，并强调镇痛、抗菌和抗癫痫领域是特别值得研究的目标。

• 旧文献显示的内容： 总结CBC在动物和体外研究中的综述文献报告了抗炎效果、减少肠道高动力、适度的啮齿动物镇痛活性，以及可能的神经生物学或抗增殖相关性，但这些信号尚未成为支持面向患者主张的强有力证据。

• 安全警告： 2024年CBC综述明确指出，尽管缺乏确立临床疗效或安全性的证据，非处方CBC产品已经在销售。

• 休斯顿人的要点： CBC属于科学上可信的次要大麻素类别，值得更多研究，而非已经经过验证的临床活性类别。

萜烯证据概况：OilWell RSO的芳香维度

萜烯主张比大麻素主张需要更严格的解释。许多萜烯文献来自单一化合物、精油、非大麻植物或临床前模型，而非来自人类对大麻配方的对照研究。2024年的增效效应综述特别强调了这一点：萜烯的生物活性是合理且有时令人信服的，但人类中临床上显著的增效效应的强有力证据仍然有限。

OilWell的RSO包含5%的七种萜烯：柠檬烯、香叶烯、石竹烯、蒎烯、芳樟醇、蛇麻烯和萜品油烯。以下是科学对每种萜烯的描述：

柠檬烯（柑橘香）

• 证据概况： 主要为综述和临床前研究，具有有用的安全文献。

• 潜在活性： 2021年的一篇综述将柠檬烯描述为一种多功能单萜烯，具有抗氧化、抗炎、心脏保护、胃保护、免疫调节等潜在活性，但这些主张的绝大部分来自非人类或非大麻文献。

• 安全性说明： 柠檬烯的氧化产物，特别是氢过氧化物，在临床上是相关的接触性过敏原，在斑贴试验文献中很重要。

• 休斯顿人的要点： 柠檬烯具有生物活性且广泛讨论，但大麻特定的治疗主张应保持保守，除非在人类中得到直接支持。

香叶烯

• 证据概况： 主要为临床前研究，人类证据非常有限。

• 研究总结： 2021年关于香叶烯的综述描述了其抗焦虑、抗氧化、抗炎和镇痛特性，并讨论了可能的机制，但明确指出缺乏人类研究。

• 解释注意事项： 香叶烯在消费者语言中常被提及，仿佛它是一种已被证明具有镇静作用的萜烯，能够解释“懒人效应”或睡眠效果。这种主张比当前人类证据所支持的更强。

• 休斯顿人的要点： 香叶烯是一种具有合理临床前生物活性的萜烯，但关于情绪、疼痛或镇静的具体临床主张仍然缺乏确凿的人类证据。

石竹烯（β-石竹烯 – 胡椒/香料）

• 证据概况： 在机制上最有趣的萜烯之一，因为它直接与大麻素系统相关，但主要为临床前研究。

• 为何突出： 2021年专注于β-石竹烯的综述将其描述为一种选择性的CB2受体激动剂，这在讨论大麻萜烯时尤为重要，因为它在药理学上而非纯粹芳香意义上具有意义。

• 研究主题： 综述文献反复讨论了抗炎、免疫调节、抗氧化、神经保护、胃保护等作用，但人类临床确认仍然有限。

• 休斯顿人的要点： β-石竹烯可能是萜烯中与大麻素系统最相关的候选者，但仍不应被描述为已被临床证明对常见归因的结果有效。

蒎烯（森林清新）

• 证据概况： 有前景的临床前文献，人类临床确认薄弱。

• 大脑健康框架： 2021年关于蒎烯和芳樟醇作为基于萜烯的大脑健康药物的综述发现，抗氧化、抗炎和神经保护信号值得未来研究，但也强调证据主要是临床前的，设计良好的临床试验仍然缺乏。

• 解释注意事项： 蒎烯可靠地改善记忆、提高注意力或抵消THC相关认知效应的主张仍然是有趣的假设，而非确定的临床事实。

• 休斯顿人的要点： 蒎烯值得科学关注，但强有力的认知相关主张应被视为探索性的。

芳樟醇（花香，薰衣草）

• 证据概况： 与蒎烯类似：大量临床前兴趣，有限的直接临床确认。

• 研究总结： 芳樟醇在压力、情绪和大脑健康药理学中反复被讨论。2021年大脑健康综述发现足够的临床前信号，值得在神经和精神背景下继续研究，同时仍然强调缺乏强有力的人类试验。

• 其他文献： 单独的综述文献讨论了可能的抗抑郁机制和神经药理学相关性，但这仍然是一个转化而非确定的临床故事。

• 安全性说明： 与柠檬烯类似，氧化的芳樟醇氢过氧化物在皮炎文献中被认定为过敏原。

• 休斯顿人的要点： 芳樟醇作为一种具有生物活性的萜烯在科学上是可信的，但当前的证据支持谨慎表述，而非坚定的治疗承诺。

蛇麻烯（泥土，木质）

• 证据概况： 具有转化潜力，但仍处于早期阶段。

• 范围综述发现： 2024年的范围综述分析了340篇文章，发现广泛的临床前证据支持抗炎和其他生物效应，一些啮齿动物研究甚至表明通过CB1和腺苷A2a途径的类大麻素特性。

• 解释注意事项： 这些发现对于假设生成很有价值，但尚未确立在疼痛、炎症或情绪结果中的一致人类疗效。

• 休斯顿人的要点： 蛇麻烯是本列表中较有研究价值的萜烯之一，但仍远未达到临床确定的程度。

萜品油烯（松木，果香，清新）

• 证据概况： OilWell配方中临床特征最少的萜烯之一。

• 系统综述发现： 2021年关于萜品油烯的综述筛选了2,449条记录，纳入了57项研究，得出结论认为萜品油烯具有多种报道的生物效应，但证据基础仍然主要由计算机模拟、体外和动物研究主导，而非人类试验。

• 解释注意事项： 即使是最近的大麻增效效应综述，也将萜烯的益处描述为探索性的，而非已确立的特定化合物临床效应。

• 休斯顿人的要点： 萜品油烯具有生物学意义，但在所列萜烯中，其临床发展尤其不足。

研究局限性和解释：休斯顿人需要知道什么

• 证据基础极不均衡。 CBD和delta-9 THC可以支持最详细的人类相关陈述；其余部分则需要更谨慎。

• 全大麻提取物数据、纯化分子数据、半合成大麻素数据和单独萜烯数据不可互换。 大麻写作中的一个常见错误是让一个类别的证据代表另一个类别。

• 次要大麻素和萜烯之所以在商业上具有吸引力，正是因为它们研究不足， 但这也意味着围绕它们的主张往往被夸大。

• 产品质量与分子身份同样重要。 标签不准确、污染、合成副产物、剂量变异和依赖于途径的药代动力学都会实质性地影响现实世界产品中的解释。

• 对于THCa来说，化学决定命运： 储存和加热可以通过将酸性大麻素转化为中性大麻素（如THC）来改变实际暴露谱。

常见的夸大陈述：保护休斯顿人免受误导信息的影响

• 夸大陈述： CBN是一种经过临床验证的睡眠大麻素。
  更准确的表述： CBN的具体睡眠证据仍然薄弱且过时，尚未发现强有力的经过验证的试验基础。

• 夸大陈述： 香叶烯是一种经过验证的人类镇静剂，可靠地解释“懒人效应”。
  更准确的表述： 香叶烯具有合理的临床前生物活性，但直接支持这一常见主张的人类证据有限。

• 夸大陈述： 一般来说，萜烯在患者中具有经过验证的增效效应。
  更准确的表述： 增效假设具有影响力且值得研究，但强有力的临床证据仍然有限且高度依赖于特定化合物。

• 夸大陈述： THCa总是非精神活性的。
  更准确的表述： THCa本身不是THC，但加热和加工可以将THCa转化为THC，改变实际暴露。

• 夸大陈述： Delta-8 THC是安全的，因为它来源于大麻。
  更准确的表述： Delta-8 THC具有精神活性，在药理学上接近delta-9 THC，并且通常与制造和测试问题纠缠在一起。

OilWell配方的实际要点：这对您意味着什么

• OilWell配方中证据最充分的活性成分是CBD和delta-9 THC。

• Delta-8 THC不是一种微不足道或纯粹温和的成分； 它是一种精神活性大麻素，其安全性和有效性特征不如delta-9 THC完善。

• THCa会随着加工而显著变化， 不应以相同方式解释生用、轻微处理和加热形式。

• CBG、CBN和CBC在科学上是可信的，但与CBD和THC相比，在临床上仍不成熟。

• 列出的萜烯可能在香气、风味和某些生物活性方面非常重要， 但特定化合物的人类治疗主张应谨慎提出，仅在直接支持的情况下。

OilWell的RSO配方：完整开源规格

RSO舌下油配方

大麻素	含量（毫克）
CBD	4,500
CBG	3,000
Delta-8 THC	6,000
THCa	1,500
Delta-9 THC	90
CBN	750
CBC	750
总大麻素	16,590

• 规格： 30毫升瓶
• 每毫升活性大麻素含量： 553毫克
• 活性萜烯： 5%（柠檬烯、香叶烯、石竹烯、蒎烯、芳樟醇、蛇麻烯、萜品油烯）
• 载体： 有机MCT油
• 剂量： 带刻度滴管，0.1毫升增量

RSO电子烟弹配方

大麻素	百分比
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• 规格： 1克电子烟弹
• 活性萜烯： 5%+
• 兼容性： 510螺纹通用电池
• 注意： THCa在电子烟温度（400-450°F）下自动脱羧为delta-9 THC

萜烯谱（两种产品）

• 柠檬烯（柑橘香）
• 香叶烯
• 石竹烯（β-石竹烯 – 胡椒/香料）
• 蒎烯（森林清新）
• 芳樟醇（花香，薰衣草）
• 蛇麻烯（泥土，木质）
• 萜品油烯（松木，果香，清新）

为何OilWell的RSO不同：为休斯顿人总结

1. 七种大麻素，而非一种。 传统RSO以THC为主。OilWell的配方包含CBD、CBG、delta-8 THC、THCa、delta-9 THC、CBN和CBC，以获得更广泛的治疗潜力。

2. 保留萜烯。 传统RSO通过溶剂和热破坏了萜烯。OilWell包含5%的活性萜烯，具有明确的七种萜烯谱，以获得更好的风味和潜在的增效效应。

3. THCa作为单独成分。 传统RSO完全脱羧。OilWell保留了1,500毫克的THCa，因此您可以选择：生用以获得非精神活性益处，或在家中脱羧以获得完全精神活性效力。

4. 减少delta-9 THC的主导地位。 传统RSO中delta-9 THC占60-90%。OilWell的配方仅使用90毫克的delta-9 THC，同时加入6,000毫克的delta-8 THC，并将其余部分分配给其他大麻素。

5. 两种产品形式。 Simpson仅设想了一种形式：注射器中的油。OilWell提供30毫升的舌下油和1克的电子烟弹，每种形式针对不同的需求。

6. 无溶剂生产。 传统RSO使用石脑油或异丙醇。OilWell的产品不含溶剂——仅有机MCT油和经过实验室测试的大麻素。

7. 实验室测试和标准化。 传统RSO没有实验室测试。OilWell的产品经过第三方测试，包括效力、萜烯、农药、重金属、残留溶剂和微生物污染物。

8. 开源配方。 Simpson免费赠送他的油。OilWell销售专业产品，并公布完整配方，因此您可以在需要时自行制作。

9. 符合农场法案。 传统RSO是非法的。OilWell的产品delta-9 THC含量低于0.3%，可在全国范围内合法购买、持有和运输。

10. 患者控制的效力。 传统RSO始终具有精神活性。OilWell的THCa允许您选择：白天非精神活性使用或脱羧后的完全效力。

如何使用OilWell的RSO：为休斯顿人的实用指南

入门：第一步

1. 咨询您的医疗保健提供者。 在开始任何新的补充剂之前，特别是如果您有医疗状况或正在服用药物，请与您的医生交谈。这对于在MD安德森、休斯顿卫理公会或迈克尔·E·德贝基退伍军人医疗中心等机构接受治疗的休斯顿人尤其重要。

2. 从低剂量开始，缓慢增加。 从小剂量（0.25至0.5毫升舌下）开始，并在增加剂量前至少等待2小时以评估效果。个体反应因体重、代谢、耐受性和其他因素而异。

3. 选择您的形式。 决定您需要快速缓解（电子烟）还是持续缓解（舌下）。请参阅本指南前文的“何时使用每种形式”表格。

4. 决定精神活性。 如果您希望在白天使用产品而不影响工作，请生用舌下油（不加热）。如果您希望获得精神活性效果，请在家中脱羧油或使用电子烟弹。

脱羧说明：在家中激活THCa

如果您选择在家中脱羧OilWell的舌下油以将THCa转化为delta-9 THC，请按照以下步骤操作：

1. 预热烤箱 至260°F（125°C）。使用烤箱温度计验证温度——许多烤箱的实际温度可能高于或低于设定值。

2. 转移所需油量 从原始瓶中倒入耐热玻璃容器。使用小玻璃罐或烤盘。不要使用塑料或金属容器。

3. 将容器 放在铺有烘焙纸的烤盘上。这样便于操作并防止溢出。

4. 烘烤45至60分钟。 这将约88%的THCa转化为delta-9 THC。油在加热过程中可能会稍微变暗。

5. 让其冷却 后再处理。容器会很热。

6. 将脱羧后的油 转移回原始瓶中或单独的容器中储存。明确标记以避免与生油混淆。

转化计算： 1,500毫克THCa → 脱羧后约1,315毫克delta-9 THC。加上配方中现有的90毫克delta-9 THC，这将使瓶中的总delta-9 THC含量达到约1,405毫克。

剂量指南：找到您的最佳剂量

状况	起始剂量（舌下）	注意事项
化疗引起的恶心	0.5毫升	治疗前1小时；电子烟用于突发恶心
慢性疼痛（白天）	0.3毫升生用	非精神活性，功能性缓解
慢性疼痛（夜间）	0.5-1.0毫升脱羧	结合疼痛缓解与CBN睡眠支持
睡眠支持	1.0-2.0毫升	提供25-50毫克CBN
焦虑（白天）	0.3毫升生用	CBD和CBG无损伤缓解焦虑
焦虑（夜间）	1.0毫升	包含CBN的全谱大麻素谱

滴定提示： 每2-3天将剂量增加0.25毫升，直到找到最小有效剂量。大麻素并非越多越好。

安全和预防措施：在休斯顿负责任地使用RSO

1. 损伤警告： 在精神活性大麻素影响下，请勿驾驶或操作机械。这在休斯顿尤为重要，因为交通和长途通勤是日常生活的一部分。

2. 药物相互作用： 大麻素可能与药物相互作用，包括血液稀释剂、抗抑郁药和镇静剂。如果您正在服用任何处方药，请咨询您的医生。

3. 怀孕和哺乳： 如果您怀孕或正在哺乳，请勿使用大麻素产品。对胎儿和婴儿发育的潜在风险尚不完全了解。

4. 放在儿童无法触及的地方。 将产品安全存放在儿童防护包装中。意外的儿童接触是一个严重的公共卫生问题。

5. 从低剂量开始，缓慢增加。 过量使用可能导致焦虑、恐慌、心动过速或其他不良反应。使用电子烟弹时尤为重要，因为起效迅速。

6. 如果您有以下情况，请咨询医生： 心脏病、精神疾病、药物滥用史或任何其他医疗状况。

7. 休斯顿特定资源：

   • 德克萨斯中毒控制网络： 1-800-222-1222（用于意外过量或不良反应）
   • 休斯顿警察局（非紧急）： 713-884-3131（用于有关当地大麻法律的问题）
   • MD安德森癌症中心： 对于考虑将RSO纳入治疗计划的癌症患者
   • 迈克尔·E·德贝基退伍军人医疗中心： 对于患有PTSD或慢性疼痛的退伍军人

法律注意事项：在休斯顿安全使用RSO

1. 联邦合法性： OilWell的RSO符合农场法案，在销售时delta-9 THC含量低于0.3%。在联邦法律下合法。

2. 德克萨斯州法律： 含delta-9 THC低于0.3%的大麻衍生产品在德克萨斯州合法。然而，一些地方执法机构可能尚未完全了解大麻和大麻的区别。在运输产品时，请随身携带分析证书（COA）。

3. THCa转化： THCa在加热时会转化为delta-9 THC。如果您在家中脱羧油，最终产品将含有显著更多的delta-9 THC，并可能在德克萨斯州法律下被视为大麻。在私人场所负责任地使用和持有脱羧后的油。

4. 药物测试： Delta-8 THC和活化的delta-9 THC可能导致药物测试阳性。如果您需要接受工作场所的药物测试，请在使用这些产品之前咨询您的雇主或法律专业人士。

5. 驾驶： 在德克萨斯州，任何精神活性物质（包括大麻）影响下驾驶都是非法的。即使产品合法，损伤也是不允许的。

6. 旅行： 即使产品符合农场法案，也不要携带大麻素产品跨越州界。联邦法律仍然认为大麻非法，各州法律也有所不同。

7. 国际旅行： 切勿携带大麻素产品进行国际旅行。许多国家有严格的毒品法律，一些国家对持有大麻有严厉的处罚。

常见问题：休斯顿的RSO

OilWell的RSO在休斯顿合法吗？

是的。OilWell的RSO符合农场法案，在销售时delta-9 THC含量低于0.3%。在联邦法律和德克萨斯州法律下均合法。然而，如果您在家中脱羧油，最终产品将含有显著更多的delta-9 THC，并可能在德克萨斯州法律下被视为大麻。负责任地使用和持有脱羧后的油。

OilWell的RSO会让我兴奋吗？

这取决于。该产品含有THCa，其生用形式为非精神活性。如果您生用舌下油（不加热），您不会兴奋。如果您在家中脱羧油或使用电子烟弹，THCa将转化为delta-9 THC，您将体验到精神活性效果。

OilWell的RSO与CBD油有何不同？

CBD油通常仅含CBD，且浓度较低。OilWell的RSO含有七种大麻素（CBD、CBG、delta-8 THC、THCa、delta-9 THC、CBN、CBC），浓度更高（每毫升553毫克），并包含活性萜烯。这种多大麻素、多萜烯的方法旨在提供更广泛的治疗潜力。

我可以用OilWell的RSO治疗癌症吗？

OilWell的RSO未经FDA评估用于治疗癌症。虽然临床前研究表明大麻素可能具有抗癌特性，但尚无人类临床试验证明RSO或任何大麻油能治愈癌症。在改变癌症治疗计划之前，请务必咨询您的肿瘤医生。MD安德森和休斯顿卫理公会等机构可以提供关于将大麻素纳入您的护理中的指导。

如何脱羧OilWell的RSO？

要脱羧舌下油，请将烤箱预热至260°F（125°C）。将所需量的油转移到耐热玻璃容器中，放在烤盘上，烘烤45至60分钟。这将THCa转化为delta-9 THC。让油冷却后再处理。

OilWell的RSO能保存多久？

舌下油在阴凉避光处保存时，保质期为1年。电子烟弹的保质期为6个月。两种产品均应远离热、光和湿气以保持效力。

我可以携带OilWell的RSO旅行吗？

只要OilWell的RSO保持其原始、符合农场法案的形式（delta-9 THC含量低于0.3%），您可以在德克萨斯州内旅行。不要携带产品跨越州界，因为联邦法律仍然认为大麻非法。切勿携带大麻素产品进行国际旅行。

OilWell的RSO会在药物测试中显示阳性吗？

Delta-8 THC和活化的delta-9 THC可能导致药物测试阳性。如果您需要接受工作场所的药物测试，请在使用这些产品之前咨询您的雇主或法律专业人士。生用、未脱羧的油（仅THCa）不太可能导致阳性结果，但仍然存在风险。

我应该服用多少OilWell的RSO？

从低剂量（0.25至0.5毫升舌下）开始，并在增加剂量前至少等待2小时以评估效果。个体反应因人而异。有关特定病症的建议，请参阅本指南前文的剂量指南。

我可以使用OilWell的配方自制RSO吗？

可以。OilWell在本指南中公布了完整配方。您可以采购单个大麻素馏出物和分离物，按照公布的比例组合，并自行制作。这是OilWell开源理念的一部分。

如何储存OilWell的RSO？

将舌下油和电子烟弹存放在阴凉避光的地方，远离热、光和湿气。舌下油可以在室温下储存，但冷藏可能延长其保质期。不要冷冻油，因为这可能导致MCT载体分离。

我可以与其他药物一起使用OilWell的RSO吗？

大麻素可能与药物相互作用，包括血液稀释剂、抗抑郁药和镇静剂。如果您正在服用任何处方药，请在使用OilWell的RSO之前咨询您的医生。

OilWell的RSO对宠物安全吗？

不安全。OilWell的RSO是为人类使用而配制的，含有可能对宠物不安全的大麻素浓度。有关宠物专用配方，请参阅OilWell关于我们页面上发布的CBD黄金膏配方。

我多久能感受到OilWell RSO的效果？

• 舌下油（生用或脱羧）： 15至45分钟起效，1至2小时达到峰值，持续4至6小时
• 电子烟弹： 1至2分钟起效，10至15分钟达到峰值，持续2至4小时

我可以在白天使用OilWell的RSO吗？

可以，如果您生用舌下油。这提供了大麻素暴露而无精神活性损伤，适合白天使用。如果需要保持清醒，请避免使用电子烟弹和脱羧后的油。

OilWell的RSO与传统RSO有何不同？

OilWell的RSO比传统RSO更安全、更标准化且更多功能。它包含七种大麻素和活性萜烯，经过实验室测试以确保安全性和效力，并通过THCa提供患者控制的效力。传统RSO以THC为主，未标准化，且始终具有精神活性。

在休斯顿哪里可以购买OilWell的RSO？

您可以在oilwellcbd.com在线购买OilWell的RSO，并在休斯顿当日送达或全国运输。您也可以访问我们位于休斯顿蒙特罗斯社区的零售店，地址是810 Richmond Ave, Houston, TX 77006。

OilWell RSO的退货政策是什么？

OilWell提供30天满意保证。如果您对购买不完全满意，请通过[email protected]联系我们，我们将全额退款或换货。

如何联系OilWell Cannabis？

• 电话： (832) 416-2816
• 电子邮件： [email protected]
• 网站： oilwellcbd.com
• Instagram： @oilwellcbd
• 地址： 810 Richmond Ave, Houston, TX 77006

营业时间

• 周一至周四： 上午10:00 – 晚上7:00
• 周五至周六： 上午10:00 – 晚上10:00
• 周日： 上午10:00 – 下午4:00

最终思考：休斯顿的RSO未来

休斯顿是一座重视创新、韧性和社区的城市。从能源行业到德克萨斯医疗中心，我们习惯于用尖端解决方案解决复杂问题。但在大麻方面，许多休斯顿人仍然感到被过时的法律和有限的选择所困。

对于许多人来说，Rick Simpson油代表着希望——希望缓解慢性疼痛，希望改善睡眠，希望找到一种天然的药物替代品。但缺乏教育的希望可能是危险的。这就是我们创建这份指南的原因：为休斯顿人提供诚实、基于科学的信息，帮助他们对RSO做出明智的决定。

OilWell Cannabis建立在三个原则之上：可及性、透明度和诚信。我们相信，大麻药物应该对每个需要它的人开放，而不仅仅是那些拥有医疗卡或深厚口袋的人。我们相信公布我们的配方，这样没有人会被排除在大麻素的益处之外。我们相信说出真相——即使这不是人们想听到的。

休斯顿的RSO未来是光明的。随着法律的演变和研究的进展，我们将继续创新——为我们的社区带来更安全、更有效和更可及的大麻素产品。但无论情况如何变化，我们对诚实教育的承诺将始终如一。

如果您正在考虑RSO，我们鼓励您将这份指南作为起点。与您的医生交谈，咨询我们的团队，并做出适合您的决定。请记住：在OilWell，我们不仅仅是销售产品——我们正在建立一个基于科学、透明度和为真实的人提供真实解决方案的运动。

感谢您信任我们的健康和好奇心。我们很荣幸能成为休斯顿迈向更好大麻获取和更好大麻素教育之旅的一部分。

准备好尝试OilWell的RSO了吗？

购买RSO舌下油 | 购买RSO电子烟弹 | 完整RSO指南

有问题吗？ 请致电(832) 416-2816或发送电子邮件至[email protected]。我们随时为您提供帮助。

ENGLISH

Rick Simpson Oil (RSO) in Houston: The Complete Guide by OilWell Cannabis

Why Houston Needs Honest RSO Education

Houston is a city of pioneers — energy innovators, medical trailblazers at the Texas Medical Center, and veterans who’ve served our country. But when it comes to cannabis, Houston residents face a frustrating paradox: we’re surrounded by world-class healthcare, yet many of us struggle to access safe, reliable, and legal cannabis medicine.

This is especially true for those battling chronic pain, chemotherapy side effects, PTSD, or sleep disorders. Traditional pharmaceuticals often come with harsh side effects or addiction risks. Meanwhile, the black market offers no quality control, no consistency, and no legal protection. For many Houstonians, Rick Simpson Oil (RSO) represents hope — but hope without education can be dangerous.

That’s why we created this guide. We’re OilWell Cannabis, Houston’s trusted cannabinoid authority since 2019. Our founder, Colin Valencia, grew up in McAllen along the border, where he saw firsthand how limited medical options can be. He built OilWell to bring real solutions to real people — not just in Houston, but across Texas and beyond.

This guide is different from anything else you’ll find about RSO. We don’t just tell you what RSO is — we show you the complete science behind it, the legal framework that makes it accessible, and the exact formulas we use in our products. Most importantly, we tell you the truth: what RSO can realistically help with, what it can’t, and how to use it safely in Houston’s unique legal and healthcare landscape.

The Rick Simpson Story: From Personal Crisis to Global Movement

Who Was Rick Simpson?

Rick Simpson wasn’t a doctor, scientist, or medical professional. He was a power engineer from Amherst, Nova Scotia, who became one of the most influential figures in cannabis history almost by accident.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath was brutal: persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine couldn’t adequately treat. The medications he was prescribed either didn’t help or made things worse. When he asked his doctor about cannabis as an alternative, the request was refused.

Simpson’s interest in cannabis deepened after he learned about a 1974 study funded by the National Institutes of Health. Conducted at the Medical College of Virginia, the study found that THC slowed or shrank tumors in mice. Ironically, the study was originally designed to demonstrate cannabis harm, not benefit. Though its findings were never replicated in controlled human cancer trials, this research became a foundational reference point for Simpson’s later advocacy.

The turning point came in 2003. Simpson noticed three bumps on his arm that his doctor diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days.

It’s crucial to understand what this story is — and what it isn’t. There’s no independent medical verification of Simpson’s outcome. No biopsy confirmation, no clinical follow-up, no peer-reviewed documentation exists. But while these events can’t be evaluated as medical evidence, they became the origin story of Rick Simpson Oil and the foundation of everything that followed.

The Crusade Begins: Spreading the Oil

After his 2003 experience, Simpson became a man on a mission. Operating from his property in Maccan, Nova Scotia, he began producing concentrated cannabis oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions ranging from cancer and chronic pain to diabetes, infections, glaucoma, arthritis, depression, and insomnia.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, featured testimonials from people he’d treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. Distributed freely online, Run From The Cure became one of the most widely shared cannabis advocacy films of its era. For many people around the world — including here in Houston — it was their first introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada, relocating first to Croatia and later to the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson maintained a consistent and uncompromising position: he believed that cannabis oil — particularly high-THC oil made according to his specific method — could cure cancer and many other diseases. He also believed that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

This conspiratorial framing is important to acknowledge. It reflects a worldview shared by many in the early cannabis movement and helps explain why RSO became culturally significant. But it’s also crucial to evaluate Simpson’s specific medical claims against the actual evidence — which we’ll do in detail later in this guide.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. Here’s a detailed breakdown of the protocol as Simpson described it:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized starting with very small doses to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of this slow ramp-up was to build THC tolerance gradually and minimize disruption from psychoactive effects. By the end of this escalation period — roughly four to five weeks in — the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration Methods

• Primary method — oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.

• Secondary method — topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.

• Not recommended as primary — inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.

• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the “high” discourage them from continuing the protocol.

• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.

• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-Protocol Maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and Lifestyle Recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.

• He wasn’t as specific or systematic about dietary protocols compared to his highly detailed oil protocol — his dietary advice was secondary and general.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.

• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.

• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.

• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the scientific literature.

• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself. This is why it’s so important for Houstonians to consult with their oncologists at world-class institutions like MD Anderson or Houston Methodist before making any treatment decisions.

What Was Traditional RSO? Understanding the Original Product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. Here’s what the original product was like:

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization — the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes — now a dark, cannabinoid-rich liquid — were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark — nearly black — thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.

• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.

• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.

• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene Content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and Testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is difficult to verify without lab testing — leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s Claims vs. The Evidence: What the Science Actually Says

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer — including terminal cases — and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

It’s important to evaluate these claims against the actual evidence base, using the same standards applied throughout this guide.

What Simpson Wasn’t

Simpson wasn’t a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.

• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.

• These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Doesn’t Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.

• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.

• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.

• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.

• Health Canada has never approved RSO or cannabis oil as a cancer cure.

• The National Center for Complementary and Integrative Health (NCCIH) explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term “RSO” itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today. This is why honest education is so important for Houstonians considering RSO — especially those being treated at world-class cancer centers like MD Anderson or Baylor St. Luke’s.

The Legacy of Rick Simpson: How RSO Evolved

The term “RSO” is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial — he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas we’ll discuss later in this guide.

Traditional RSO vs. Modern Formulated RSO: What’s the Difference?

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products:

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They’re informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

1. Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

2. Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

3. THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

4. Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

5. Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety: Why Modern Extraction Matters

Traditional RSO production used naphtha or isopropyl alcohol — neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Isopropyl alcohol, while cleaner than naphtha, is also not intended for internal consumption. Incomplete solvent purging — which is very difficult to verify without analytical chemistry equipment — leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution is particularly important for Houstonians. Our city is home to some of the world’s leading medical institutions, and patients here expect the highest standards of safety and quality. At OilWell, we believe that solvent safety isn’t just a regulatory requirement — it’s a moral obligation to the people who trust us with their health.

The Decarboxylation Question: Patient-Controlled Potency

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near the boiling point of the solvent — was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material — including THCa, CBDa, CBGa, and others — were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage — because THCa can convert to THC under heating or over time.

Terpene Loss in Traditional RSO: Why It Matters

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes — including myrcene, limonene, and pinene — having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile. The entourage effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now: How Research Has Evolved

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This isn’t necessarily a moral failing — it’s a description of the environment in which he operated.

This guide takes a fundamentally different approach. We apply a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science.

Where Simpson relied on personal testimony, we rely on published literature and institutional sources. This is why our RSO guide is the most comprehensive and trustworthy resource available for Houstonians — because we hold ourselves to the same evidence standards we apply to everyone else.

Simpson’s Protocol vs. Modern Dosing: Why They’re Different

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation isn’t straightforward — the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.

• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.

• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.

• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in this guide and by responsible titration principles that account for the safety profile of each individual cannabinoid.

OilWell Cannabis: Houston’s RSO Authority

The Origin of OilWell: From Border Hustle to Medical Innovation

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border.

McAllen is a city of contrasts — vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of retail and healthcare. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. Many of his best friends were killed or ended up in prison because of the associated dangers. He faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin didn’t fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach.

Bentley’s Story: The Dog Who Changed Everything

The company’s origin story begins with a dog named Bentley. Bentley wasn’t just a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley wasn’t an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin wasn’t ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD — through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He’d never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It wasn’t a cure, but it was a lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This wasn’t placebo effect — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection.
• Dementia led him to CBC’s role in neurogenesis.
• Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction.
• Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin’s Personal Battle: PTSD and Benzo Addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat that’s notoriously difficult and dangerous — using the cannabinoid knowledge he’d developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD.

This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t. His personal experience makes OilWell credible in a way no corporate cannabis brand can match.

Formulas Used by Doctors: From Pets to People

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13: Houston’s Trusted Cannabis Authority

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023. These features covered Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This commitment to honest education — not hype, not false promises — is what sets OilWell apart in Houston’s cannabis market.

Today: Houston’s RSO Leader

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed.

OilWell’s products aren’t mass-produced — they’re carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas.

Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy: Accessibility, Control, Transparency

OilWell’s RSO isn’t traditional Rick Simpson Oil. It’s a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas. OilWell publishes their complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who can’t afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured, lab-tested, standardized product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The research section of this guide represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what’s well-supported, what’s emerging, and what’s overstated.

Farm Bill Compliance: The THCa Legal Framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-Source Formulas: Why We Publish Everything

OilWell publishes their complete RSO formulas — every cannabinoid, every milligram amount, every percentage — in public documents including this guide. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is straightforward: if someone can’t afford OilWell’s products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this guide are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy didn’t start with RSO — it started with Bentley. On our About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets — The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos isn’t a marketing strategy. It’s the foundational behavior of the company.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase.

The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3 — Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production: Safety First

OilWell’s RSO isn’t an extraction product in the traditional sense. It’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed earlier in this guide.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader OilWell Product Portfolio: Beyond RSO

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It’s particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations — OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

OilWell’s RSO Products: Complete Specifications

Two Product Formats: Sublingual Oil and Vape Cartridge

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids:
  • CBD: 4,500 mg
  • CBG: 3,000 mg
  • Delta-8 THC: 6,000 mg
  • THCa: 1,500 mg
  • Delta-9 THC: 90 mg
  • CBN: 750 mg
  • CBC: 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide — OilWell’s full product guide with science, competitive analysis, protocols, and ordering information.

When to Use Each Format: A Practical Guide for Houstonians

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison: OilWell RSO vs. Alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP Dispensary RSO

Dimension	TCUP Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

Why this matters for Houstonians: The Texas Compassionate Use Program (TCUP) requires a medical card and limits access to specific qualifying conditions. OilWell’s RSO is accessible to any adult 21 or older, ships directly to your door, and includes a full spectrum of cannabinoids — not just THC. For many Houstonians, this makes OilWell the more practical choice.

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

Why this matters for Houstonians: Hemp CBD products are widely available, but they lack the full cannabinoid spectrum and psychoactive options that many RSO users seek. OilWell’s formula offers 16 times the total cannabinoids, includes psychoactive options, and provides a more comprehensive therapeutic profile.

OilWell RSO vs. Traditional Illegal RSO

This comparison is presented in the Traditional RSO vs. modern formulated RSO table earlier in this guide. OilWell’s product solves the key problems of traditional RSO: solvent safety, standardization, lab testing, terpene preservation, and patient-controlled potency.

Condition-Specific Usage Context for Houstonians

Important disclaimer: The following usage contexts are informed by cannabinoid research and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment. This is especially important for Houstonians who work in the energy sector, healthcare, or other professions where impairment isn’t an option.
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment. This is ideal for Houstonians dealing with high-stress jobs, traffic, or family responsibilities.
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Houston-specific resources:

• MD Anderson Cancer Center: For cancer patients, consult with your oncologist about integrating RSO into your treatment plan.
• Houston Methodist Pain Management: For chronic pain patients, discuss cannabinoid options with your pain specialist.
• Michael E. DeBakey VA Medical Center: Veterans with PTSD or chronic pain should consult with their VA providers about cannabinoid therapy options.
• Texas Poison Control Network: For accidental overconsumption or adverse reactions, call 1-800-222-1222.

Delivery and Global Accessibility: Getting RSO to Houstonians

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, we ship nationwide and internationally.

Houston Same-Day Delivery

Zone	Coverage	Delivery Fee	Typical Turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center — the world’s largest medical complex with over 10 million patient visits annually — reflects OilWell’s commitment to accessibility for the patients who need it most. This is especially important for cancer patients undergoing treatment at MD Anderson or Houston Methodist, who may be too fatigued or ill to travel to a dispensary.

Nationwide Shipping

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International Shipping

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson couldn’t ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally — completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology — a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

The Science Behind OilWell’s RSO: What the Research Actually Says

Research Method: How We Evaluate Evidence

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base isn’t evenly distributed.

Of the compounds in OilWell’s RSO formula, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline: What the NIH and FDA Say

• The National Center for Complementary and Integrative Health (NCCIH) states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.

• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.

• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.

• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoid Evidence Profiles

CBD (Cannabidiol) — 4,500 mg in OilWell’s Sublingual Formula

• Evidence profile: Strongest human evidence in OilWell’s formula, especially when CBD is studied as a purified product rather than as a loose wellness ingredient.

• What is best supported: Purified CBD has the most credible human evidence in seizure disorders, particularly for rare forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. This is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.

• Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified.

• Pain research: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.

• Sleep research: A 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments.

• Safety and interaction concerns: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations.

• Bottom line for Houstonians: CBD is the most evidence-developed nonintoxicating cannabinoid in OilWell’s formula, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing.

CBG (Cannabigerol) — 3,000 mg in OilWell’s Sublingual Formula

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse.

• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established.

• Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions.

• Caution: One of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

• Bottom line for Houstonians: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid.

Delta-8 THC — 6,000 mg in OilWell’s Sublingual Formula

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.

• Comparative pharmacology: A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity.

• Public-health literature: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns.

• Manufacturing context: The recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter.

• Bottom line for Houstonians: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid) — 1,500 mg in OilWell’s Sublingual Formula

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.

• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing.

• Psychoactivity: The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.

• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.

• Bottom line for Houstonians: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC.

Delta-9 THC — 90 mg in OilWell’s Sublingual Formula

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids in OilWell’s formula, but also the clearest adverse-effect burden.

• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage.

• Pain evidence: A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.

• Pharmacokinetics and onset: Classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk.

• Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.

• Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products.

• Bottom line for Houstonians: Delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in OilWell’s formula.

CBN (Cannabinol) — 750 mg in OilWell’s Sublingual Formula

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data.

• What it is often marketed for: Sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.

• Best direct review for the sleep claim: The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.

• Broader sleep literature: The 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.

• Chemical context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.

• Bottom line for Houstonians: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base.

CBC (Cannabichromene) — 750 mg in OilWell’s Sublingual Formula

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.

• Pharmacology and therapeutic interest: The 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.

• What the older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.

• Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

• Bottom line for Houstonians: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

Terpene Evidence Profiles: The Aromatic Dimension of OilWell’s RSO

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

OilWell’s RSO includes seven terpenes at 5 percent: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Here’s what the science says about each:

Limonene (Citrus-Bright)

• Evidence profile: Largely review and preclinical, with useful safety literature.

• Potential activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.

• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.

• Bottom line for Houstonians: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans.

Myrcene

• Evidence profile: Mostly preclinical, with very limited human evidence.

• Research summary: The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.

• Interpretation caution: Myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.

• Bottom line for Houstonians: Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene (β-Caryophyllene – Pepper/Spice)

• Evidence profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.

• Why it stands out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.

• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.

• Bottom line for Houstonians: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still shouldn’t be described as clinically proven for the outcomes commonly attributed to it.

Pinene (Forest-Fresh)

• Evidence profile: Promising preclinical literature, weak human clinical confirmation.

• Brain-health framing: The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.

• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

• Bottom line for Houstonians: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory.

Linalool (Floral, Lavender)

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation.

• Research summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.

• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story.

• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.

• Bottom line for Houstonians: Linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises.

Humulene (Earthy, Woody)

• Evidence profile: Translationally interesting, but still early.

• Scoping-review findings: A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.

• Interpretation caution: Those findings are valuable for hypothesis generation, but they don’t yet establish consistent human efficacy across pain, inflammation, or mood outcomes.

• Bottom line for Houstonians: Humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled.

Terpinolene (Piney, Fruity, Sparkling)

• Evidence profile: One of the least clinically characterized terpenes in OilWell’s formula.

• Systematic-review findings: The 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.

• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.

• Bottom line for Houstonians: Terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically.

Research Limits and Interpretation: What Houstonians Need to Know

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution.

• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.

• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.

• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.

• For THCa in particular, chemistry is destiny: Storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements to Avoid: Protecting Houstonians from Misinformation

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for OilWell’s Formulas: What This Means for You

• The most evidence-developed actives in OilWell’s formulas are CBD and delta-9 THC.

• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.

• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.

• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.

• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

OilWell’s RSO Formulas: Complete Open-Source Specifications

RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)
CBD	4,500
CBG	3,000
Delta-8 THC	6,000
THCa	1,500
Delta-9 THC	90
CBN	750
CBC	750
Total Cannabinoids	16,590

• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Dosing: Graduated dropper with 0.1 mL increments

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Format: 1-gram cartridge
• Live terpenes: 5%+
• Compatibility: 510-thread universal battery
• Note: THCa automatically decarboxylates to delta-9 THC at vaping temperature (400-450°F)

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

Why OilWell’s RSO Is Different: A Summary for Houstonians

1. Seven cannabinoids, not one. Traditional RSO was THC-dominant. OilWell’s formula includes CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC for broader therapeutic potential.

2. Terpenes preserved. Traditional RSO destroyed terpenes through solvent and heat. OilWell includes live terpenes at 5% with a defined seven-terpene profile for better flavor and potential entourage effects.

3. THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. OilWell preserves THCa at 1,500 mg so you can choose: use it raw for non-psychoactive benefits or decarboxylate it at home for full psychoactive potency.

4. Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell’s formula uses only 90 mg delta-9 THC while incorporating 6,000 mg delta-8 THC and distributing the rest across other cannabinoids.

5. Two product formats. Simpson envisioned only one format: a syringe of oil. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each designed for different needs.

6. Solvent-free production. Traditional RSO used naphtha or isopropyl alcohol. OilWell’s products contain no solvents — just organic MCT oil and lab-tested cannabinoids.

7. Lab-tested and standardized. Traditional RSO had no lab testing. OilWell’s products are third-party tested for potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants.

8. Open-source formulas. Simpson gave his oil away for free. OilWell sells a professional product and publishes the complete recipe so you can make your own if you prefer.

9. Farm Bill compliant. Traditional RSO was illegal. OilWell’s products contain less than 0.3% delta-9 THC and are legal to purchase, possess, and ship nationwide.

10. Patient-controlled potency. Traditional RSO was always psychoactive. OilWell’s THCa allows you to choose: non-psychoactive for daytime use or full potency after decarboxylation.

How to Use OilWell’s RSO: A Practical Guide for Houstonians

Getting Started: The First Steps

1. Consult your healthcare provider. Before starting any new supplement, especially if you have a medical condition or are taking medications, talk to your doctor. This is especially important for Houstonians being treated at institutions like MD Anderson, Houston Methodist, or the Michael E. DeBakey VA Medical Center.

2. Start low, go slow. Begin with a small dose (0.25 to 0.5 mL sublingual) and wait at least 2 hours to assess effects before increasing. Individual responses vary based on body weight, metabolism, tolerance, and other factors.

3. Choose your format. Decide whether you need fast relief (vape) or sustained relief (sublingual). Refer to the “When to Use Each Format” table earlier in this guide.

4. Decide on psychoactivity. If you want to use the product during the day without impairment, use the sublingual oil raw (no heat). If you want psychoactive effects, decarboxylate the oil at home or use the vape cartridge.

Decarboxylation Instructions: Activating THCa at Home

If you choose to decarboxylate OilWell’s sublingual oil to convert THCa into delta-9 THC, follow these steps:

1. Preheat your oven to 260°F (125°C). Use an oven thermometer to verify the temperature — many ovens run hot or cold.

2. Transfer the desired amount of oil from the original bottle into an oven-safe glass container. Use a small glass jar or ramekin. Do not use plastic or metal.

3. Place the container on a baking sheet lined with parchment paper. This makes it easier to handle and prevents spills.

4. Bake for 45 to 60 minutes. This converts approximately 88% of the THCa into delta-9 THC. The oil may darken slightly during the process.

5. Let it cool before handling. The container will be hot.

6. Transfer the decarboxylated oil back into the original bottle or into a separate container for storage. Label it clearly to avoid confusion with raw oil.

Conversion math: 1,500 mg THCa → approximately 1,315 mg delta-9 THC after decarboxylation. Combined with the existing 90 mg delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC in the bottle.

Dosing Guidelines: Finding Your Sweet Spot

Condition	Starting Dose (Sublingual)	Notes
Chemotherapy nausea	0.5 mL	1 hour before treatment; vape for breakthrough
Chronic pain (daytime)	0.3 mL raw	Non-psychoactive, functional relief
Chronic pain (nighttime)	0.5-1.0 mL decarbed	Combines pain relief with CBN sleep support
Sleep support	1.0-2.0 mL	Delivers 25-50 mg CBN
Anxiety (daytime)	0.3 mL raw	CBD and CBG without impairment
Anxiety (nighttime)	1.0 mL	Full cannabinoid profile with CBN

Titration tip: Increase your dose by 0.25 mL every 2-3 days until you find the minimum effective dose. More is not always better with cannabinoids.

Safety and Precautions: Using RSO Responsibly in Houston

1. Impairment warning: Do not drive or operate machinery while under the influence of psychoactive cannabinoids. This is especially important in Houston, where traffic and long commutes are part of daily life.

2. Drug interactions: Cannabinoids can interact with medications, including blood thinners, antidepressants, and sedatives. Consult your doctor if you’re taking any prescription medications.

3. Pregnancy and nursing: Do not use cannabinoid products if you are pregnant or nursing. The potential risks to fetal and infant development are not well understood.

4. Keep out of reach of children. Store products securely and in child-resistant packaging. Accidental pediatric exposure is a serious public health concern.

5. Start low, go slow. Overconsumption can cause anxiety, panic, tachycardia, or other adverse effects. This is especially important with the vape cartridge, which has a rapid onset.

6. Consult your doctor if you have: heart conditions, psychiatric disorders, a history of substance use disorder, or any other medical condition.

7. Houston-specific resources:

   • Texas Poison Control Network: 1-800-222-1222 (for accidental overconsumption or adverse reactions)
   • Houston Police Department (Non-Emergency): 713-884-3131 (for questions about local cannabis laws)
   • MD Anderson Cancer Center: For cancer patients considering RSO as part of their treatment plan
   • Michael E. DeBakey VA Medical Center: For veterans with PTSD or chronic pain

Legal Considerations: Using RSO Safely in Houston

1. Federal legality: OilWell’s RSO is Farm Bill compliant and contains less than 0.3% delta-9 THC at the point of sale. It is legal under federal law.

2. Texas state law: Hemp-derived products containing less than 0.3% delta-9 THC are legal in Texas. However, some local law enforcement agencies may not be fully educated on the distinction between hemp and marijuana. Keep your Certificate of Analysis (COA) with you when transporting the product.

3. THCa conversion: THCa converts to delta-9 THC when heated. If you decarboxylate the oil at home, the resulting product will contain significantly more delta-9 THC and may be considered marijuana under Texas law. Use and possess decarboxylated oil responsibly and in private settings.

4. Drug testing: Delta-8 THC and activated delta-9 THC can trigger positive drug tests. If you are subject to workplace drug testing, consult with your employer or a legal professional before using these products.

5. Driving: It is illegal to drive under the influence of any psychoactive substance in Texas, including cannabis. Even if the product is legal, impairment is not.

6. Travel: Do not cross state lines with cannabinoid products, even if they are Farm Bill compliant. Federal law still considers marijuana illegal, and state laws vary.

7. International travel: Never travel internationally with cannabinoid products. Many countries have strict drug laws, and some have severe penalties for cannabis possession.

Frequently Asked Questions: RSO in Houston

Is OilWell’s RSO legal in Houston?

Yes. OilWell’s RSO is Farm Bill compliant and contains less than 0.3% delta-9 THC at the point of sale. It is legal under federal law and Texas state law. However, if you decarboxylate the oil at home, the resulting product will contain significantly more delta-9 THC and may be considered marijuana under Texas law. Use and possess decarboxylated oil responsibly.

Will OilWell’s RSO get me high?

It depends. The product contains THCa, which is non-psychoactive in its raw form. If you use the sublingual oil raw (no heat), you will not get high. If you decarboxylate the oil at home or use the vape cartridge, the THCa will convert to delta-9 THC, and you will experience psychoactive effects.

How is OilWell’s RSO different from CBD oil?

CBD oil typically contains only CBD, often at lower concentrations. OilWell’s RSO contains seven cannabinoids (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) at much higher concentrations (553 mg per mL) and includes live terpenes. This multi-cannabinoid, multi-terpene approach is designed to provide broader therapeutic potential.

Can I use OilWell’s RSO for cancer?

OilWell’s RSO has not been evaluated by the FDA for the treatment of cancer. While preclinical research suggests that cannabinoids may have anticancer properties, no human clinical trial has demonstrated that RSO or any cannabis oil cures cancer. Always consult with your oncologist before making any changes to your cancer treatment plan. Institutions like MD Anderson and Houston Methodist can provide guidance on integrating cannabinoids into your care.

How do I decarboxylate OilWell’s RSO?

To decarboxylate the sublingual oil, preheat your oven to 260°F (125°C). Transfer the desired amount of oil to an oven-safe glass container, place it on a baking sheet, and bake for 45 to 60 minutes. This converts THCa into delta-9 THC. Let the oil cool before handling.

How long does OilWell’s RSO last?

The sublingual oil has a shelf life of 1 year when stored in a cool, dark place. The vape cartridge has a shelf life of 6 months. Both products should be stored away from heat, light, and moisture to preserve potency.

Can I travel with OilWell’s RSO?

You can travel within Texas with OilWell’s RSO as long as it remains in its original, Farm Bill-compliant form (less than 0.3% delta-9 THC). Do not cross state lines with the product, as federal law still considers marijuana illegal. Never travel internationally with cannabinoid products.

Will OilWell’s RSO show up on a drug test?

Delta-8 THC and activated delta-9 THC can trigger positive drug tests. If you are subject to workplace drug testing, consult with your employer or a legal professional before using these products. The raw, non-decarboxylated oil (THCa only) is less likely to trigger a positive test, but there is still a risk.

How much OilWell’s RSO should I take?

Start with a low dose (0.25 to 0.5 mL sublingual) and wait at least 2 hours to assess effects before increasing. Individual responses vary. Refer to the dosing guidelines earlier in this guide for condition-specific recommendations.

Can I make my own RSO using OilWell’s formula?

Yes. OilWell publishes the complete formula in this guide. You can source the individual cannabinoid distillates and isolates, combine them according to the published ratios, and make your own version. This is part of OilWell’s open-source philosophy.

How do I store OilWell’s RSO?

Store both the sublingual oil and vape cartridge in a cool, dark place away from heat, light, and moisture. The sublingual oil can be stored at room temperature, but refrigeration may extend its shelf life. Do not freeze the oil, as this can cause the MCT carrier to separate.

Can I use OilWell’s RSO with other medications?

Cannabinoids can interact with medications, including blood thinners, antidepressants, and sedatives. Consult your doctor before using OilWell’s RSO if you are taking any prescription medications.

Is OilWell’s RSO safe for pets?

No. OilWell’s RSO is formulated for human use and contains concentrations of cannabinoids that may be unsafe for pets. For pet-specific formulas, refer to the CBD golden paste recipe published on OilWell’s About Us page.

How quickly will I feel the effects of OilWell’s RSO?

• Sublingual oil (raw or decarboxylated): 15 to 45 minutes onset, 1 to 2 hours peak, 4 to 6 hours duration
• Vape cartridge: 1 to 2 minutes onset, 10 to 15 minutes peak, 2 to 4 hours duration

Can I use OilWell’s RSO during the day?

Yes, if you use the sublingual oil in its raw, non-decarboxylated form. This provides cannabinoid exposure without psychoactive impairment, making it suitable for daytime use. Avoid the vape cartridge and decarboxylated oil if you need to stay clear-headed.

How does OilWell’s RSO compare to traditional RSO?

OilWell’s RSO is safer, more standardized, and more versatile than traditional RSO. It includes seven cannabinoids and live terpenes, is lab-tested for safety and potency, and offers patient-controlled potency through THCa. Traditional RSO was THC-dominant, unstandardized, and always psychoactive.

Where can I buy OilWell’s RSO in Houston?

You can purchase OilWell’s RSO online at oilwellcbd.com and have it delivered same-day in Houston or shipped nationwide. You can also visit our retail location at 810 Richmond Ave, Houston, TX 77006 in the Montrose neighborhood.

What is the return policy for OilWell’s RSO?

OilWell offers a 30-day satisfaction guarantee. If you are not completely satisfied with your purchase, contact us at [email protected] for a full refund or exchange.

How can I contact OilWell Cannabis?

• Phone: (832) 416-2816
• Email: [email protected]
• Website: oilwellcbd.com
• Instagram: @oilwellcbd
• Address: 810 Richmond Ave, Houston, TX 77006

Business Hours

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

Final Thoughts: RSO in Houston’s Future

Houston is a city that values innovation, resilience, and community. From the energy sector to the Texas Medical Center, we’re used to solving complex problems with cutting-edge solutions. But when it comes to cannabis, many Houstonians still feel stuck between outdated laws and limited options.

Rick Simpson Oil represents hope for many — hope for relief from chronic pain, hope for better sleep, hope for a natural alternative to pharmaceuticals. But hope without education can be dangerous. That’s why we created this guide: to give Houstonians the honest, science-based information they need to make informed decisions about RSO.

OilWell Cannabis was built on three principles: accessibility, transparency, and integrity. We believe that cannabis medicine should be available to everyone who needs it, not just those with medical cards or deep pockets. We believe in publishing our formulas so that no one is shut out of the benefits of cannabinoids. And we believe in telling the truth — even when it’s not what people want to hear.

The future of RSO in Houston is bright. As laws evolve and research advances, we’ll continue to innovate — bringing safer, more effective, and more accessible cannabinoid products to our community. But no matter how much things change, our commitment to honest education will remain the same.

If you’re considering RSO, we encourage you to use this guide as a starting point. Talk to your doctor, consult with our team, and make the decision that’s right for you. And remember: at OilWell, we’re not just selling products — we’re building a movement based on science, transparency, and real solutions for real people.

Thank you for trusting us with your health and your curiosity. We’re honored to be part of Houston’s journey toward better cannabis access and better cannabinoid education.

Ready to try OilWell’s RSO?

Buy RSO Sublingual Oil | Buy RSO Vape Cartridge | Complete RSO Guide

Questions? Call us at (832) 416-2816 or email [email protected]. We’re here to help.

---